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ABSTRACT

Nucleic acids are macromolecules in cells for storing and transferring
genetic information. Moreover, nucleic acids, especially RNAs, can fold into
well-defined 3D structures and catalyze biochemical reactions. As ubiquitous
biological molecules in all living systems, nucleic acids are important drug
targets, and they can also be used in diagnostics and therapeutics. Structural
information of nucleic acids provides the foundation for DNA and RNA function
studies. X-ray crystallography has been a useful tool for structural studies of
bio-macromolecules at atomic level.

There are two major problems in

macromolecular crystal structure determination: phasing and crystallization.
Although selenium derivatization is routinely used for solving novel protein
structures through the MAD phasing technique, the phase problem is still a

critical issue in nucleic acid crystallography. The covalent seleniumderivatization of nucleic acids has been proven to be a useful strategy for
solving the phase problem in nucleic acid X-ray crystallography. Besides the
facilitation of nucleic acid crystallography, there is also a wide range of other
applications for selenium-derivatized nucleic acids (SeNA).
The investigation presented in this dissertation mainly focuses on the
following research subjects
(1) Synthesis and characterization of selenium-derivatized nucleic acids for
X-ray crystallography, especially phosphoroselenoate RNAs. They are
generated and used for crystallization.
(2) Application of selenium-derivatized RNA for RNA interference.
Phosphoroselenoate RNAs are tested for RNAi activities.
(3) Synthesis and characterization of the uridine 5’-triphosphate modified
with selenium at position 4.
(4) Facile synthesis and antitumor activities of selenium modified
deoxyribonucleosides. MeSe-thymidine nucleosides have shown antitumor
activity in cell assays.
.
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1.

INTRODUCTION

1.1 RNA crystallography
In 1953, the DNA double helix model was proposed by Watson and Crick,
while at that time scientists still had no clue about the structure and function of
the RNA molecule.[1] Until 1974, after the X-ray crystal structure of L-shaped
transfer RNA (tRNA) was determined, the role of RNA in protein biosynthesis
started to be revealed.
RNA is an important mediator of gene expression.

mRNA transfers

genetic information out of the nucleus and serves as a template to guide the
synthesis of corresponding proteins. There are also other RNA species playing
important roles in the protein synthesis machinery, such as rRNA and tRNA. In
biological regulation, researchers previously focused more on protein biology,
because protein possesses more diverse structures and biological functions.
However, since massive discoveries on non-coding and regulatory RNA
molecules, like microRNA [2] and riboswitch,[3] researchers found that nature has
very smart and much varied designs for the regulation. Beside regulation of
proteins, RNAs, especially mRNAs, are also regulated.[4] These RNA regulations
can be performed by both protein and RNA. Furthermore, non-coding RNAs,
such as microRNAs, can also regulate proteins expression through RNA-protein
interactions.[5] The study of the function and structure of these non-coding and
regulatory RNA molecules has become an increasingly active research field.
Like proteins, RNA molecules also have complicated structures and
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abilities to catalyze enzymatic reactions.[6] Understanding the biological activities
of RNA molecules also requires the knowledge about the structure and
conformational dynamics of these molecules. Another important advance in RNA
crystallography after the tRNA structure was the crystal structure of several types
of ribozymes, such as hammerhead ribozyme (1994),[7] P4-P6 domain of the
Tetrahymena group I intron (1996),[8] and hepatitis delta virus (HDV) ribozyme
(1998),[9] which represented a growing interest in the RNA crystallography field.
After that, many more crystal structures of functional RNAs were determined,
such as ribosomal RNA,

[10]

hepatitis C virus ribosome entry site

[11]

and

riboswitches.[12] With the assistance of these RNA structures, scientists are able
to discover more insights into biological systems.
In biomacromolecular X-ray crystallography, crystallization and phasing
problem are the two major limiting factors. Crystallization of biomacromolecules
is

the

most

unpredictable

step

in

determining

the

structure

of

the

biomacromolecules. Comparing with protein crystallization, RNA crystallization
has some unique difficulties. A crystal is regularly assembled by a large numbers
of molecules, which are held by non-covalent interactions (crystal contacts).[13]
While proteins have a variety of structural and chemical groups on the surface to
make crystal contacts, the surface of a RNA molecule is full of negatively charged
repetitive phosphate groups, which make the crystal packing much more difficult.
Moreover, crystal diffraction signals are usually weaker from the RNA crystals
due to the loose packing and higher solvent content in the RNA crystals. In
addition, RNA typically has weaker tertiary interactions, which result in higher
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flexibility of structures; thus it is more difficult to prepare conformationally
homogeneous RNA samples. Besides crystallization, the other difficulty in nucleic
acid crystallography is how to solve the phase problem.[14] Several methods have
been developed for solving the phase problem.

[15]

The major technical

breakthrough for solving the protein phase problem was MAD (multi-wavelength
anomalous dispersion) phasing technique with selenomethionine (SeMet)
derivatized protein.[16] For nucleic acids, due to the lack of convenient heavy
atom derivatization with high stability, the phase problem is still a bottleneck.
Our group pioneered and developed selenium derivatized nucleic acid
(SeNA) strategy to solve the phase problem in nucleic acid crystallography,
through the MAD phasing technique. What the phase problem is and how
selenium-derivatization facilitates the RNA crystallography are explained in detail
in the following sections.

1.2 Selenium derivatization for nucleic acid crystallography - why we need
selenium derivatization for nucleic acids X-ray crystallography and how to
introduce selenium into RNA?

1.2.1 The phase problem in X-ray crystallography
In a biomacromolecular X-ray crystallography experiment, there are three
major steps, crystallization, data collection and data analysis (Figure 1.1)

[17]

.

Firstly, enough of pure macromolecules has to be prepared and crystallized, then
the X-ray diffraction data of the crystals can be collected. If good quality X-ray
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diffraction data is obtained; it can be analyzed and refined to reconstruct the
electron density map of the macromolecule.

Figure1.1 Steps for solving a novel macromolecular X-ray crystal structure.
Illustration of why selenium derivatization is needed for nucleic acids X-ray
crystallography.
In the data analysis step; the reconstruction of the electron density map in
order to acquire the electron density at a position (xyz) from the diffraction data
requires us to apply Fourier transformation (equation expressed as following) [15].
ρ(xyz ) = 1/V S│Fhkl│exp(iαhkl) exp(-2πihx+ky+lz)
Two components on the right side of the equation, structure-factor amplitude
│Fhkl│ and phase αhkl associated with │Fhkl│, are needed for calculation of the
electron density at a position (xyz). The amplitude │Fhkl│ can be measured from
the reflection intensity. However, the phase information αhkl is not directly
available from the experiment. This problem is called the phase problem of X-ray
crystallography.
Phase is a descriptive term for electromagnetic (EM) waves, such as X-ray.
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For two waves with same or similar wavelength, when they are added together,
there will be interference. Depending on their relative phases, the interference
could be either constructive or destructive. There is either constructive or
destructive interference among crystal diffracted X-ray beams.

The phase

information of diffracted beams is required for determination of the atom position
in the structure. In fact, the phase information is very important to produce the
right structure.

[15]

For example, if an electron density map for protein A is

desired and is calculated by combining the amplitude of protein A and phase of
protein B, a structure like protein B could be generated for protein A, which
actually is a wrong structure for protein A.

1.2.2 Methods to solve the phase problem
There are several methods to solve the phase problem in X-ray
crystallography:

direct

methods,

molecular

replacement,

isomorphous

replacement and anomalous scattering. [15]

Direct methods [15]
In the beginning, the molecules crystallographers were working on were
usually simple molecules and crystallographers could often make a good guess
on the conformation of the molecule. Then the guess could be analyzed by
calculating a diffraction pattern and comparing it to the observed one. This
method requires high resolution data (<1.2 Å) and could be used for small
molecules (<1000 non-hydrogen atoms). Currently, programs like Shake-and-
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Bake, SHELXD and SHARP, are still using direct methods to find the
substructure of heavy-atom.

Molecular replacement
To carry out the molecular replacement method, a good homolog model
for the unknown molecule has to be available.

[18]

As a rule of thumb, the model

normally has to share at least 25% sequence similarity to that of the unknown
molecule, usually much greater similarity is required for success. Patterson
method is usually used first to determine the orientation of the model in the new
unknown molecule.

The oriented model can be then placed into the

crystallographic unit cell with the translation function. The phase information can
then be extracted from the model.

Isomorphous replacement
Isomorphous derivatives are the derivatives that have same space group
and unit cell as native molecule.

If one or several heavy-atoms could be

introduced into native molecules at specific binding site(s) without changing the
crystalline order, such isomorphous heavy-atom derivatives can be used to solve
the phase problem of the native molecule.

[15, 17]

The principle of isomorphous

replacement is that isomorphous heavy-atom derivatization will introduce an
intensity difference, which can be measured and used to estimate the position of
the heavy-atom using the direct method or Patterson method. Once the position
of the heavy-atom is located, its corresponding phase can be calculated and
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used to solve the phase of the native molecule.
Soaking the crystal in a solution containing heavy-atom compound can
introduce the heavy-atom into the crystal. Another method to introduce the
heavy-atom to crystal is growing the crysal with heavy-atom containing
molecules[18]. Using one type of heavy-atom derivative in single isomorphous
replacement (SIR) alone will acquire two possible solutions to the phase. This is
called phase ambiguity.

More than one type of heavy-atom derivatives are

needed to acquire the only one solution of the phase. This method is called
multiple isomorphous replacements (MIR).

Anomalous scattering [15, 17]
Similar to what happens in isomorphous replacement, introducing of
heavy-atom to the crystal also results in considerable differences in structurefactor amplitudes due to anomalous scattering. These differences could be used
to solve the phase of the original molecule.

Compared with isomorphous

replacement, differences in structure-factor amplitudes generated by anomalous
scattering are usually smaller.

Therefore, anomalous scattering has higher

requirement on preciseness of intensities measurement.

However, the

advantage of the anomalous scattering is that there is no need to grow several
different heavy-atom derivatized crystals. Different X-ray wavelengths can be
used in anomalous scattering on one heavy-atom derivatized crystal to obtain
several different sets of data. Anomalous scattering can be combined with SIR to
break the phase ambiguity in SIR, and this method is called SIRAS (single

8

isomorphous replacement with anomalous scattering). Generally, at least three
different X-ray wavelengths are needed in anomalous scattering to solve the
phase problem and this method is called multiple wavelength anomalous
diffraction (MAD).

1.2.3 Selenium derivatization of macromolecules and MAD phasing
Molecular replacement is the most convenient method for structure
determination, if a good homology model is available, and then there will be no
need to obtain a heavy-atom derivative. On the other hand, for new structures,
the phase problem has to be solved through heavy-atom methods. Then the
question is should we go for isomorphous replacement or anomalous scattering?
With isomorphous replacement, there are several problems.

[15]

First,

different heavy-atom derivatives and native molecule crystals have to be
obtained. Second, there could be nonisomorphism among these crystals. Third,
all heavy atom positions have to be located and refined. While with MAD
technique, it is unable to help on all of the problems of isomorphous replacement.
However, it can overcome the nonisomorphism problem since only one type of
heavy-atom derivative is needed.
There are many particular heavy-atoms that could be used for MAD
phasing.[16, 19] The choice of atoms is mainly limited by the absorption edge of
the element, which is related with the practical wavelengths of X-ray used in the
diffraction experiments. The most popular anomalous scattering atom used for
proteins is selenium.

Because, firstly, the K absorption edge of selenium is
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0.9795 Ǻ, which is an ideal wavelength for X-ray diffraction experiments in most
synchrotron radiation sources.

[15]

Secondly, selenium is within the same group

as oxygen and sulfur in periodic table, which means there will be insignificant
structure perturbation.[20] Thirdly, the building block (amino acid) selenium analog
is available, which is selenomethionine (SeMet) with selenium substitution of
sulfur in methionine.[21] Fourthly, SeMet can be conveniently incorporated into
proteins by expressing proteins in Met- strain with selenomethionine rich
media.[22] Therefore, with advances in the instruments and technical details for
MAD, the majority of novel protein structures are now solved by the MAD
phasing technique.

1.2.4 The advantages of SeNA for nucleic acids X-ray crystallography
The phase problem of nucleic acid X-ray crystallography can also be
solved by these protein techniques stated above. The comparison of these
techniques for solving nucleic acid phase problem is shown in Table 1.1. In order
to use direct method, high resolution diffraction data is required, which usually
does not happen on a regular basis.[14] Molecular replacement is the most
convenient method and can be applied for low resolution data; though,
comparing with protein, it is less successful for structures that have highly
repetitive units stacked together, especially in DNA. For novel structures, MAD
phasing technique provides a good solution to the phase problem of nucleic acid
X-ray crystallography. A specific U1A method for RNA MAD phasing, in which
RNA was co-crystallized with SeMet protein U1A (a RNA binding protein), was
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reported by Ferre-D’ Amare and Doudna group.[9, 23] Although the U1A method
has been used to solve two ribozyme structures, it is a considerably laborintensive approach. Direct and convenient heavy atom derivatization methods
for nucleic acids have not been well developed yet.
Without methods to prepare selenium nucleic acid derivatives, bromine (K
edge 0.9202 Ǻ) derivatives are usually used for nucleic acid crystallography to
solve the phasing problem.[24] Halogen derivatives work fine with B-form DNA.
However, in A-form DNA or RNA, halogen derivatives generate significant
structural perturbations. Furthermore, due to the chemical properties of halogens,
there are limited sites on nucleic acids suitable for halogen modification, usually
at the 5-position of pyrimidines. It was also found that the bromine modification
was not very stable during X-ray radiation. Debromination can happen with a mild
dose of X-ray radiation.
Compared with traditional halogen derivatization, selenium derivatization
is more stable under X-ray exposure.

[25]

In addition, the anomalous diffraction

signals from bromine and selenium are comparable, thus the phasing power of
selenium atoms for nucleic acid derivatizations are similar to bromine.[26] Since
selenium is in the same group with oxygen in the periodic table, there are more
site choices for selenium derivatization on nucleic acids. There are many oxygen
atoms on nucleic acids, which in principle can all be selenium incorporation sites.
It has been observed from nucleic acid crystal structures with selenium
modifications, that selenium did not induce significant structure perturbation in
the structure.[27] We also found that the high quality 2’MeSe-derivatized DNA
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crystals can be obtained overnight. [20]
Nucleic acids are easier to prepare and purify in comparison with proteins.
Se-derivatized RNA and DNA can also facilitate solving the phase problem of
proteins that bind with nucleic acid. For enzymes in the nucleotidyl transferases
superfamily, instead of mutating the protein active site, selenium atomic mutation
on DNA or RNA may also be an option to inactivate the enzymes, plus phase
information could be obtained without expressing proteins in Met- strain.

More

detailed information about the relationship of selenium and nucleotidyl
transferases is discussed in instruction 1.3.1.

Table 1.1 Methods to solve the phase problem for nucleic acid crystal structures

1.2.5 Methods for introducing selenium into RNA
As described above, to determine the phase by isomorphous replacement
or anomalous scattering in nucleic acid crystallography, heavy atoms have to be
introduced into nucleic acid crystals.

[15]

There are several techniques to

introduce the heavy atoms into nucleic acids, including enzymatic incorporation,
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synthetic incorporation, soaking, and co-crystallization.

[28]

A comparison of these

methods is shown in Table 1.2. The problem with soaking method is that there is
non-specific binding of heavy-atom compounds to nucleic acids, while cocrystallization may also change the structure of nucleic acid due to ion
replacement.

[28]

The benefit of covalent incorporation, like enzymatic

incorporation and synthetic incorporation, is that the position of heavy atom is
known, which is very important for initial localization of the heavy atom.
However, these are no natural building block analogs available to nucleic acids,
like selenomethionine (SeMet) to proteins. Artificial heavy-atom derivatized
nucleic acids have to be specially prepared.
In the terms of preparing large scale RNA for crystallization, enzymatic
incorporation and synthetic incorporation methods both have advantages and
disadvantages.[29] For synthetic incorporation with the solid phase synthesizer,
the advantage is the convenience to prepare a large quantity of oligonucleotides
and also the capability for almost any types of modifications. The primary
disadvantage is the limit on length (<50 nt) due to significantly low yield for longer
oligonucleotides.

Considering the length of most structurally interesting RNA

molecules and demands on the equipment for most laboratories that are not
equipped with solid phase synthesizers, enzymatic synthesis is the generally
preferred procedure in most RNA laboratories. Very long RNA strands and a
large quantity of RNA molecules could be obtained from enzymatic synthesis.
For the enzymatic method, in order to get modified RNA, modified NTP analogs
have to be prepared. Moreover, the modification can be inserted into RNA only if
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the RNA polymerase is able to take the modified NTP analogs in as substrate.
T7 RNA polymerase from bacteriophages is the most commonly used
RNA polymerase for in vitro preparation of RNA. The polymerase domain of T7
RNA polymerase is homologous to that of polymerases found in DNA polymerase
I family, and shares the catalytic mechanism.

[30]

The two metal ions catalytic

mechanism of T7 RNA polymerase is illustrated in Figure 1.2.

T7 RNA

polymerase catalysis is an SN2 nucleophilic reaction. In the active site, metal ion
A lowers the pKa of 3’-OH thus increasing its nucleophilicity. Metal ion B helps to
bring in NTP, stabilizing the negative charge on the oxygens and facilitates the
pyrophosphate release.[31] When preparing modified RNAs by enzymatic
synthesis, the mechanism of T7 RNA polymerization should be definitely
considered.
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Figure 1.2. T7 RNA polymerase polymerization mechanism

When comparing 5’-(alpha-P-seleno)triphosphates (NTPαSe) to native
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NTP, there was not much difference on the yield of radioactive labeled RNA. In
the large scale preparation of RNA with much higher NTP concentrations, there
was a difference in the yields for both native RNA and PSe-RNA, especially when
dsDNA templates were used. Therefore, the protocol for large scale preparation
of PSe-RNA has to be optimized from the native NTP condition.

It was

suspected that the lower affinity of magnesium to selenium was the reason for
the lower yield of PSe-RNA. Therefore, manganese ions were tested in the
transcription and indeed improved the transcription yield.

Table 1.2. Methods for introducing selenium into nucleic acid

1.3 Other applications of Se-derivatized nucleic acids
1.3.1 Investigation of nucleotidyl-transfer reactions
Nucleotidyl-transfer reaction, in which nucleic acids get synthesized,
degraded or rearranged, is an essential chemical reaction happening in all life
forms. As a result of this reaction, genetic information gets replicated, transferred,
or destroyed, which represents the most basic cycle of the life. According to the
“RNA world hypothesis”, this reaction is one of the most ancient and fundamental
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events in the beginning of life.
The typical catalytic mechanism of nucleotidyl-transfer reaction, whether
by cleavage or ligation, usually involves one or two metal ions.

A similar

intermediate structure is shared among these nucleotidyl-transferases using two
metal ion catalysis, like DNA or RNA polymerase, some nucleases and
ribozymes.[32]

In the active site(s), metal ions are coordinated by the scissile

phosphate and also nearby amino acid residues (protein) or bases (ribozyme) to
promote the nucleophilic attack.

Examples of the catalytic mechanism for

nucleotidyl-transfer reactions are illustrated in the following sections with
discussions later about how selenium modified nucleic acids could be used for
investigation of the nucleotidyl-transfer reaction. Moreover, as discussed in 1.2.5,
the mechanism of nucleotidyl-transfer reaction must be considered for
preparation and application of selenium modified DNA and RNA.

1.3.1.1 Ribonuclease catalytic mechanism and inhibition of RNase by selenium
modification
Ribonuclease catalytic mechanism
Ribonuclease (RNase) is a type of nuclease that catalyzes the
degradation of ribonucleic acids (RNA). These enzymes could digest a variety of
RNA substrates, including dsRNA, ssRNA or RNA in RNA/DNA duplex.

For

instance, RNase H that can degrade RNA in the RNA/DNA duplex, is required in
DNA replication to remove RNA primers from Okazaki fragments.[33] The function
of RNase III like domain in Dicer is to produce small interfering RNAs (siRNA) in
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RNA induced post transcriptional gene silence mechanism.[34] RNases are also
applied to many analytical purposes, such as RNA sequencing, mapping, and
quantitation[35]. Some RNase domains are proposed drug targets in RNA virus
infections, such as the RNase H domain in retroviral reverse transcriptase.[36]
Advances in the knowledge about the catalysis of RNases provide opportunities
for better control of many essential biological processes.
RNA
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Figure 1.3. RNase H cleavage mechanism

Stepwise models for several important RNases with two metal ions
catalysis have been built based on X-ray crystal structures.
RNase H catalysis is shown in Figure 1.3.

[32]

A diagram for

The two metal ions, A and B,

which usually are Mg2+ in physiological conditions, are present in the active site
to coordinate the negatively charged phosphate backbone of RNA substrates and
acidic residues of the enzyme.

Metal ion B deprotonates the nucleophilic water

and may assist in bringing the nucleophilic water close to the scissile phosphate
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[36]

. The negative charge generated on the oxygen is stabilized by Metal ion A

and this may destabilize the substrate and promote nucleophilic attack. Later,
the substrate release may require dissociation of the metal ion B.

Inhibition of RNase by selenium modification
Extensive studies have been carried out on how to control the RNA
hydrolysis process, either to accelerate or to delay it. Recently, due to the great
desire of extending siRNA lifetime in mammalian cells for therapeutic purposes;
studies on inhibiting RNase activities with modified RNA substrate attracted lots
of research interests. A variety of chemical modifications have been tested on
RNA for RNase resistance and higher base-pairing fidelity.[37]
Our group reported previously that selenium modification at the position of
the non-bridging oxygen of RNA phosphate backbone would inhibit the RNase
activity.[38] This mechanism is proposed as reduction of magnesium ion affinity to
selenium compared with oxygen. Although due to differences in electronegativity,
selenide (Se-) should be more stable than oxide (O-) in the intermediate structure;
magnesium ions have much lower affinity to selenium than to oxygen,[38] which
may result in lose of magnesium ion interaction with RNA and a significantly
reduced turnover rate of the enzyme. Based on the RNA interference experiment
in Chapter 3, the RNA interference strength from siRNAs with selenium
modification at phosphate backbone was enhanced about one fold comparing
with native siRNA.
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1.3.1.2 Self-cleavage mechanisms of ribozymes and selenium as an atomic
probe for ribozyme catalytic studies
Ribozyme self-cleavage mechanism
The catalytic mechanism of the hammerhead ribozyme is mainly
discussed here as an example. Hammerhead ribozymes are small self-cleaving
RNAs that first were discovered in a self-cleavage sequence in small RNA
satellites of plant viruses

[39]

. A full-length active hammerhead ribozyme contains

three base-paired stems and 15 highly conserved nucleotides.[40] A proposed
one metal ion mechanism in hammerhead ribozyme catalysis is shown here
(Figure 1.4). The metal ion stabilizes the negative charge generated in the 2’
oxygen in the proposed general acid G-8 to promote nucleophilic in-line attack. [41]
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Figure 1.4. Metal ion mechanism in hammerhead ribozyme catalysis [41].
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Selenium as an atomic probe for ribozyme studies
In ribozyme studies, it is very important to discover which chemical groups
play the main role in structural conformation and which directly participate in
chemical catalysis.[42]

To answer this question, insertion of chemically modified

nucleotides into ribozyme as probe is a very useful strategy. Atomic mutation
with elements in the same group is an ideal choice because less perturbation is
expected on ribozyme structure. Changes in ribozyme turn-over rate will mainly
come from the mutation site.
Originally, there was a strong disagreement on hammerhead ribozyme
catalytic mechanism derived from biochemistry studies and the structural data. It
was caused by the absence of tertiary interaction of active site in the
hammerhead ribozyme structures.[43]

Scott and coworkers published a

Schistosma hammerhead ribozyme structure in 2006, which basically solved
most of the structure-function conflicts and organized the majority of the
biochemical data.[43] However, in Scott’s structure, no metal ion was found in the
active site.[40]
Based on other biochemical data, the metal ion should be involved in the
active site of the hammerhead ribozyme.

[44-45]

A previous experiment from our

lab carried out with an RNA substrate that had several selenium modifications on
the non-bridging oxygens of the phosphate backbone, also showed that metal
ions played an important role in catalysis. With selenium modification at
phosphate backbone and the presence of Mg2+ containing buffer, self-cleaving
activity of hammerhead ribozyme was inhibited; while with Mn2+ substitution of
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Mg2+, the activity was rescued.[38] Selenium on the phosphate backbone was
considered to produce no significant perturbation in the structures, if the
phosphate was exposed to solvent.[27] The inhibition of cleavage activity was
caused by the atomic mutation. This is an example of how selenium modified
nucleotides can be used as an atomic mutation to probe the function of chemical
groups for ribozymes.

1.3.2 Selenium and diseases
Selenium is an unusual trace element. Discovered in 1818, and named
after the goodness of the moon, this element was only known for its toxicity and
as a possible carcinogen for a long period of time.[46]

The essentiality of

selenium for life rather than a hazard was primarily recognized in the late 1950s,
which was almost one and a half centuries after the identification of selenium
element.

The systematically documented diseases caused by selenium

deficiency in humans were rare, except for the well known severe heart failure in
Keshan disease.[47] However, there is evidence from both laboratory and
observational studies suggesting that selenium may affect human health from
diverse

aspects,

such

as

immune

responses,

cancer,

HIV

infection,

cardiomyopathy, rheumatoid arthritis, asthma and Alzheimer’s disease.[48]
There were two famous randomized controlled clinical trials concerning
the investigation of selenium health benefits in the US. However, the results
coming out of these two trials were different from each other. The first study was
from Nutritional Prevention of Cancer (NPC), the result of which showed that
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prostate cancer risk was reduced by 63% for selenium enriched yeast.

[49]

In

contrast, the more recent and larger scale clinical trial result for Selenium and
Vitamin E Cancer Prevention Trial (SELECT), funded by the National Cancer
Institute (NCI) and the National Institutes of Health (NIH) showed that selenium
and vitamin E supplements, either alone or in combination, did not prevent
prostate cancer.[50] These results seem suggest that selenium may only benefit
people who have low serum selenium level. Although the result from SELECT
was a huge disappointment, as a trace element, the essentiality of selenium to
life was still indisputable.
The biological effects of selenium on life are exerted through a variety of
selenium-containing molecules in cells:

O
Se

O
OH

HSe

NH2

SeMet

OH
NH2

SeCys

Figure 1.5. Selenomethionine and Selenocysteine
In protein, selenium is inserted in two forms, selenomethionine (SeM,
SeMet) and selenocysteine (Sec, SeCys) (Figure 1.5).

[51]

No physiological

function differences were observed between proteins with selenomethionine or
methionine.

[21]

Selenoenzymes, the majority of which are involved in catalyzing

redox reactions, are generally referred as enzymes with Sec in the active sites
for specific functions. In the human genomes, there are 25 genes encoding for
30 selenoproteins.[52]

The most well studied selenoenzyme is glutathione
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peroxidase (GPx), which catalyzes the reduction of hydrogen peroxide or
phospholipid peroxide to water or corresponding alcohols using glutathione
(GSH).[53]

GPxs constitute an important part of the cell antioxidant defense

system and have also been related with oxidative stress recovery, reduction of
UV-induced DNA damage, protection against neurodegenerative diseases and
cancer prevention. [54]
Selenium levels in the body are mainly determined by the dietary selenium
content. The major natural selenium species in selenium rich plants are selenate,
SeMet, SeCys, Se-methyl-selenocysteine (MeSeCys) and g-glutamyl-SemethylSelenocysteine (GluMeSeCys).

[55]

In general selenium metabolic pathways,

selenium containing amino acids from food, such as SeMet and SeCys are
metabolized to hydrogen selenide (H2Se) through enzymatic reactions (Figure
1.6).[56]

Selenomethionine could also be incorporated into ordinary proteins

through the normal protein synthesis pathway in the place of methionine.
Inorganic selenite (SeO32–) and selenate (SeO42-) are also reduced to H2Se
through several metabolic steps involving glutathione and NADPH-dependent
reductases.[57-58] H2Se is an intermediate among several selenium pathways,
such as selenium reductive pathway, synthetic metabolism and methylation
metabolism. H2Se can be incorporated into phosphate by selenophosphate
synthetase.[59] The selenophosphate (H3PO3Se) is used to synthesize sec-tRNA,
which conducts insertion of selenocysteine into selenoproteins through the UGA
code. H2Se could also be methylated by thiol S-methyltransferase to mono-, diand tri- methylated forms, which would get out of body though breath or urine. [57]
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Nevertheless, as first proposed by Ip and coworkers, methylselenol (MeSe,
CH3SeH) was considered to be the most active metabolite of selenium
compounds in selenium chemoprevention.[60] There were many researches on
the chemprevention activities of MeSe.

Figure 1.6. Selenium metabolism pathways
Compared with the most extensively studied selenoproteins and small
selenium metabolites, it is not well-known that selenium also naturally occurs in
bases of tRNA, usually in the wobble base position, which may have some
special functions.

[61]

However, detailed studies about the natural Se-derivatized

RNAs are rather limited. Selenium was found in tRNAs, mainly in the forms of 2selenouridine and 5-[(methylamino)methyl]-2-selenouridine (mnm5se2U), as
shown in Figure 1.7. These seleno-tRNAs are usually found in species such as
Escherichia

coli,

Clostridium

sticklandii,

Methanococcus

vannielii,

and

Salmonella typhimurium.[62-65] Se-derivatization of tRNA was also surprisingly
found in mouse leukemia cells [66] and bovines.

[67]
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It is reasonable that the essentiality of selenium for life could be the
combined effects from selenoproteins, seleno-nucleic acids and selenium
metabolites in body, which increases the complexity of the evaluation of selenium
biological activities.
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In our lab, many selenium-containing nucleosides, nucleotides and nucleic
acids have been made. Considering the possible therapeutic activity of selenium
compounds, these nucleosides, nucleotides and nucleic acids have been sent for
primary anticancer, antimicrobial screenings. Some of them indeed shown
biological activities.[68] Further investigation on selenium-containing molecules for
health will definitely offer more information about this type of molecule.

1.4 Current development of SeNA for X-ray crystallography
Selenium can be incorporated in to a variety of sites of nucleic acids,
including the sugar, phosphate and base (Figure 1.8). Since 1998, our lab has
pioneered the technique advancing in this field.[69] Here is a brief summary of the
current stage of SeNA development for nucleic acid X-ray crystallography.
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Figure 1.8. Atom specific selenium replacement of oxygen in nucleic acids

1.4.1 Selenium modification at sugar
Selenium substitution of oxygen at 5’ of A, C, G, T and U as methylselenol,
was the first attempt of derivatizing nucleic acid with selenium for X-ray crystal
structure studies.

[69]

This modification was designed for terminal selenium

derivatization of nucleic acid.

Selenium containing phosphoramidites were

prepared and selenium was introduced into nucleic acids through a solid phase
synthesizer. The successful synthesis of selenium containing oligonucleotides
proved that it was possible to incorporate selenium into nucleic acid through solid
phase synthesizer.
Selenium was also introduced to 2’-position of nucleic acid as
methylselenol group through solid phase synthesis.[20, 26, 70-73] This modification
later turned out to be a great success, even more than expected. Selenium
modified DNA grew crystals in many buffer conditions of the Hampton kit
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overnight.

[20]

The comparison results showed that DNA derivatized with

selenium at 2’-position could crystallize at broader buffer condition and had better
crystallizability than native or bromine modified DNA. A high resolution selenium
derivatized small DNA duplex structure (1.28 Å) was solved by MAD with 2’methylseleno modification. Selenium derivatization was also present in the minor
groove of DNA and did not affect minor groove hydration significantly.
Micura’s group in Austria has developed strategies for solid phase
synthesis of RNA with 2’-methylseleno modifications.[74-76]

The shorter RNA

strands prepared by solid phase synthesis with site specific 2’-methylseleno
modification were linked together to form longer RNA (up to 100 nt) by T4 RNA
ligase.[75] A ligated 49 nt RNA with 6 selenium atoms was crystallized in the
same conditions as native and the crystals diffracted at about 3 Å resolution. It
was stated that, with site specific insertion, 2’-methylseleno modification did not
significantly change the global folding of RNA. As with what happened in DNA, a
crystallization screening showed that 2’-methylseleno modified RNA was able to
crystallize at broader buffer conditions than the nonmodified counterpart. Crystal
packing analysis suggested that selenium atoms may contribute to bring RNA
molecules closer to each other. [76]

1.4.2 Selenium modification at non-bridging phosphate
Egli and co-worker from Vanderbilt University developed a solid phase
synthesis method to derivatize DNA with selenium at the non-bridging phosphate
position [27]. DNA phosphoroselenoate (PSe-DNA) was demonstrated to be stable
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under crystallization conditions for months. It was reported that selenium
modification close to the 5’ end was more stable than inside positions. There
were only minimal differences between PSe-DNA structure and the native DNA
structure. The Mg2+ ion coordination was identical to that in original native DNA
structure. The PSe-DNA generated from solid phase synthesis method was a
mixture of Rp and Sp diastereomers for phosphorous chiral center and needed
further purification. Diastereomeric pure PSe-DNA could be made from
enzymatic synthesis

[77-78]

.

Our group reported a synthesis method for all

nucleoside 5’-(α-P-seleno)triphosphates and also incorporation of one of the two
NTPαSe diastereomers into RNA

[38]

. RNase resistance was observed for PSe-

RNA.

1.4.3 Selenium modification at nucleobase
Derivatives of DNA at the 4-position of thymidine (4-Se-T) have been
prepared through both solid phase synthesis and enzymatic incorporation.

[79-80]

Crystallization was attempted for solid phase synthesized 4-Se-DNA. A selenium
mediated hydrogen bond was observed in the 4-Se-DNA duplex with distance of
2.87 Å.[80] The UV-melting experiment showed that the 4-selenium modification
did not significantly affect the melting point of a 9mer DNA comparing with the
native DNA duplex, which indicated that there was not much perturbation on
base pairing.
In order to investigate whether a C-H (or CH3) group can form a hydrogen
bond with the phosphate backbone of nucleic acids, selenium was inserted into
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the 5-methyl group of thymidine.[81] A DNA duplex crystal was obtained with
selenium at 5-methyl position of thymidine from solid phase synthesis In the
crystal structure, the selenium linker extended the methyl group toward the
phosphate and the distance between the methyl and phosphate was only 2.93 Å,
which is within the normal hydrogen bond distance. The possible interaction
between methyl and phosphate was suspected to be involved in DNA duplex
unwinding by reducing the energy barrier.
Selenium was also introduced into the 6-position of guanine (6-Se-G).[82]
6-Se-DNA was co-crystallized with RNA and RNase H and the crystal structure
was determined, which was the first nucleic acid–protein complex structure with
phase solved by selenium derivatization on nucleic acid. The base pair between
6-Se-G and C was similar to a normal G-C pair with a shift of about 0.3 Å. The
overall structure of 6-Se-DNA was very similar to native DNA duplex.

29

2

PREPARATION

OF

PHOSPHOROSELENOATE

RNA FOR

X-RAY

CRYSTALLOGRAPHY
2.1 Introduction
The explosive discoveries on RNA in recent years, such as small
regulatory RNA

[2, 83]

and the riboswitch,

[3]

lead to a great demand for structural

insights of RNA and RNA related molecules. Compared with protein
crystallography, RNA crystallography has some unique problems (as discussed
in the introduction). One major problem is lack of a well developed heavy atom
derivatization method to solve the phase problem.[13] In the case of novel protein
structure, the phase problem is usually solved by selenomethionine (SeMet)
derivative via MAD phasing technique.[16,

19]

Halogen derivatives have been

traditionally used for nucleic acid heavy atom derivatization. However, halogen
derivatives usually produce crystal structures that are different from native
structures and are unstable during X-ray radiation.[24] Since 1998, Huang’s
research group has pioneered the development of selenium derivatization of
nucleic acids for X-ray crystallography.

[69]

It was found that selenium derivatives

are much more stable than halogen derivatives under X-ray radiation and less
structural perturbation has been observed for the selenium derivatives.[20, 25]
Heavy atoms can be introduced into nucleic acid through several
different ways - soaking, co-crystallization and covalent incorporation.[28] The
difficulty with the soaking method is that many heavy atom compounds do not
bind well to nucleic acids at specific sites. A co-crystallization method, using
SeMet derivatized U1A protein (a RNA binding protein), was reported by Ferre-D’
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Amare and Doudna groups.[9, 23] Although this U1A method has been used to
solve two ribozyme structures, it is a labor-intensive approach.

For direct

covalent incorporation of a heavy atom into nucleic acids, there are two methods
- enzymatic (RNA polymerase) and synthetic (solid phase synthesis).[29] A
drawback of solid phase synthesis for large-scale RNA preparation is that the
length of RNA is limited (<50 nt). To solve this problem, a T4 RNA ligase method
for RNA 2’-methylseleno modification was developed by Micura’s group to
produce longer selenium derivatized RNA.[75] For most laboratories that are not
equipped with a solid phase synthesizer and not familiar with organic synthesis,
enzymatic incorporation is a much more accessible method. A large quantity of
long RNA molecules can be obtained using enzymatic synthesis by RNA
polymerase. In addition to assisting in RNA crystallography, phosphoroselenoate
RNA (PSe-RNA) was also reported to be RNase resistant,[38] as such it serves as
a potential application for RNA interference therapeutics.
To incorporate selenium into RNA through RNA polymerase, the 5’(alpha-P-seleno) triphosphates (NTPαSe) have to be prepared and must be
capable of being accepted as substrate by RNA polymerase. We have reported
previously a method to prepare NTPαSe with protective groups on the sugar
moiety,

[38, 78]

and their incorporation into RNA by T7 RNA polymerase.

Considering the general applications of these NTPαSe, it is necessary to simplify
the synthesis method, improve the yield and carry out a full scale
characterization for these NTPαSe. In this section of the dissertation, a new
synthesis method is described in detail for preparation of NTPαSe without any
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protective groups, which greatly reduced efforts for purification and increased the
yield of NTPαSe and PSe-RNA. All of the nucleoside 5’-(α-P-seleno)triphosphate
diastereomers synthesized by the new method were characterized by NMR, MS
and HPLC and tested for RNA incorporation on multiple types of DNA templates.
Different DNA template preparation methods (single strand, plasmid and PCR)
for RNA crystallization are also described in detail to standardize the protocol. All
of the NTPαSe were purified by RP-HPLC or boronate column and purified
NTPαSes were tested for several RNA incorporations through different types of
DNA template. The PSe-RNA was purified and the selenium derivatization was
confirmed by MALDI-TOF.
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Figure 2.1. (A) NTPαSe structure. (B) Structure of Rp phosphoroselenoate RNA.

2.1.1 Brief introduction about the functional RNA molecules in this dissertation
Hammerhead ribozyme
The hammerhead ribozyme is the smallest nucleolytic ribozyme, which
can perform a site specific self-cleavage.[84] The hammerhead ribozyme was
initially found in several plant viruses for rolling cycle replication.[40] The minimal
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hammerhead ribozyme has of three base-paired stems and a conserved core of
15 nucleotides (shown in grey in Figure 2.2).

The catalytic mechanism of the

hammerhead ribozyme has been discussed in detail in the Introduction 1.3.1.2
Self-cleavage mechanisms of ribozymes and selenium as an atomic probe for
ribozyme catalytic studies. Basically, the nucleophilic attack starts from the 2’hydroxyl of a nucleotide in the conserved core to its adjacent phosphodiester
bond, and generates a 2’, 3’-cyclic phosphate and a free 5’-hydroxyl end.[85]

Figure 2.2. Secondary structure of wild type hammerhead ribozyme derived from
the satellite RNA of tobacco ringspot virus. Conserved bases are labeled in grey

West Nile virus (WNV) terminal stem-loop (SL)
The genome of WNV is a single stranded positive RNA strand (sense
strand).[86-87] There were stem-loop (SL) structures in the 5’ noncoding region of
WNV genome (SL(+)) (Figure 2.3.B).

The studies suggested that the
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complementary negative strand of this region, which also formed a SL structure
(SL(-)) (Figure 2.3.A), could serve as a promoter for replication of the positive
strand. The existence of the terminal secondary structure in the complementary
negative strand was confirmed by RNase digestion experiment.

[88]

These SL

structures are probably cell protein binding sites. Analysis of the sequence and
structure of the WNV genome can allow potential applications in the treatment
and diagnosis of West Nile Virus in humans and animals.

5’
3’
5’

A. WNV 3’ SL(-)

3’

B. WNV 5’ SL (+)

Figure 2.3. Predicted secondary structure of WNV terminal stem-loop SL (-) and
SL (+)
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P4-P6 domain of group I intron
The group I intron (400 nt) from Tetrahymena thermophila was the first
described catalytic RNA, which can self-splice itself from a ribosomal RNA
transcript. The group I intron has nine paired regions, named from P1 to P9,
which are folded into two domains - the P4-P6 domain (formed by the P5, P4, P6
and P6a helices) and the P3-P9 domain (formed by the P8, P3, P7 and P9
helices).

[89]

P4-P6 domain (160 nt) is an essential part of the group I intron from

Tetrahymena thermophila.[8] Without the P4-P6 domain, the intron is not active.
The P4-P6 domain is not only part of the catalytic core but also stabilizes the
intron and helps to bring the intron’s folding pathway together.[90] The folding P4P6 domain is independent from the rest of the intron. A secondary structure of
P4-P6 domain is shown in Figure 2.4. The crystal structure of a wild type P4-P6
domain was solved in 1996, by which the principle of folding of large ribozyme
into compact, globular structure through long-range tertiary interaction was first
revealed. A single site mutant (ΔC209) of P4-P6 domain has been reported to be
more stable and easy to crystallize,[91] and makes it a good model molecule to
demonstrate

the

crystallography.

principle

of

selenium

RNA

derivatization

for

X-ray
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3’
5’

Figure 2.4. Secondary structure of P4-P6 domain of group I intron
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Table 2.1. RNA sequences
Name

Sequences
5’-GGGAGCCCUGUCACCGGAUGUGCUUUCCGGUCUGA
UGAGUCCGUGAGGACAAAACAGGGCUCCCGAAUU-3’
5’-GGGAGCCCUGUCACCGGAUGUGCUUUCCGGUCUGA
UGAGUCCGUGAGGACGAAACAGGGCUCCCGAAUU-3’
5’-CAGCUCGCACCGUGUUAAUUGUUGUUAAUCCUCACA
AACACUACUAAGUUUGUCAGCUCACACAGGCGAACUACU
-3’
5’- AGUAGUUCGCCUGUGUGAGCUGACAAACUUAGUAGU
GUUUGAGAGGAUUAACAACAAUUAACACGGTGCGAGCU
G -3’
5’-GGGAGCCCUGUCACCGGAUGUGCUUUCCGGUCUGA
UGAGUCCGUGAGGACAAAACAGGGCUCCCGAAUU-3’

HHM
HHN
SL(-)
SL(+)
89.24
55.27

5’-GGCAACCUGAUGAGGCCGAAAGGCCGAAACGUACA-3’

44.1

5’-G GCA ACCGGAUGAGGCCGA AAGGC-3’

P4-P6

5’GGAAUUGCGGGAAAGGGGUCAACAGCCGUUCAGUACC
AAGUCUCAGGGGAAACUUUGAGAUGGCCUUGCAAAGGG
UAUGGUAAUAAGCUGACGGACAUGGUCCUAACACGCAG
CCAAGUCCUAAGUCAACAGAUCUUCUGUUGAUAUGGAU
GCAGUUC-3’

2.2 Materials and methods
2.2.1 Synthesis, characterization and purification of nucleosides 5’-(alpha-Pseleno) triphosphates
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Figure 2.5. Synthesis route of NTPαSe.
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2.2.1.1 Synthesis of NTPαSe
The following procedure was performed under argon gas with stirring
and all liquids were dried and purged with argon before use:
Tributylammonium pyrophosphate (426 mg, 0.9 mmol, 2 eq., flask 1),
individual nucleoside (varied mass, 0.45 mmol, 1 eq., flask 2), and 3H-1, 2benzothaselenol-3-one (BTSe, flask 3) (195 mg, 0.9 mmol, 2 eq., flask 3),[92-93]
were dried in separate flasks at high vacuum for 1 h. The tributylammonium
pyrophosphate (flask 1) was dissolved by DMF (0.6 mL) and TBA (1.2 mL). 2chloro-4H-1,3,2-benzodioxaphosphorin-4-one (182 mg, 0.9 mmol, 2 eq., flask 4)
was dried for 15 min, dissolved in 1.2 mL DMF and then injected into
pyrophosphate flask (flask 1). The reaction mixture was stirred under argon at
room temperature for 30 min. After that, the nucleoside (flask 2), was dissolved in
DMF (0.45 mL) ( special note: adenosine was dissolved by 0.32 mL DMF and
0.13 mL DMSO, and guanosine was dissolved by 0.225 mL DMF and 0.225 mL
DMSO). The reaction mixture (flask 1) of tributylammonium pyrophosphate and
2-chloro-4H-1,3,2-benzodioxaphosphorin-4-one was added to the dissolved
nucleoside (flask 2). After nucleoside reaction mixture (flask 2) was stirred under
argon at room temperature for 1 h, the 3H-1,2-benzothaselenol-3-one (BTSe,
flask 3), was dissolved in dioxane (1.5 ml) and added to the nucleoside reaction
mixture (flask 2). The mixture was stirred for a further hour and then water (10.2
ml, twice the reaction solution volume) was added to for hydrolyzation. Two hours
after hydrolyzation, an ethanol precipitation was performed with additional fresh
DTT (20 mM) at condition of 0.3 mM NaCl and three volumes of ethanol, -80 oC
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30 min then 14k rpm 30 min at 4 oC. The pellet was redissolved in small amount
of water and the concentration was checked by UV at 260 nm.

2.2.1.2 HPLC purification of nucleosides 5’-(alpha-P- seleno) triphosphates:
The synthesized NTPαSes were purified by reverse phase HPLC (RPHPLC). NTPαSe was eluted using a combination of two solvents at varying
proportions: buffer A (20mM TEAAc in water) and buffer B (20mM TEAAc, 50%
water, 50% acetonitrile).

Analytic HPLC program for ATPαSe, CTPαSe and

GTPαSe was 20 min 12.5% acetonitrile with 20 mM TEA·Ac buffer (pH7) at 1
mL/min. Analytic HPLC program for UTPαSe was 20 min 20% ethanol with 20
mM TEA·Ac buffer (pH7) at 1 mL/min. Each diastereomer was collected
seperately. Fractions were lyophylizated and one additional ethanol precipitation
(as described in 2.2.1.1) was performed for desalting before NMR data collection
or transcription.

2.2.1.3 Boronate column chromatography of nucleosides 5’-(alpha-P-seleno)
triphosphates
Wash buffer: 1 M TEABC buffer was prepared by bubbling CO2 through
a solution with 28.2 ml triethylamine in 140 ml H2O at 4 oC until pH drops to 9.5
and then bring the solution volume up to 200 ml. The pH was tested each time
before the buffer was used. The prepared TEABC buffer was stored at 4 oC.
Elution buffer: 22.5 mL water and 14 µl of 80% acetic acid were mixed
well, and the pH value observed was 4.5, which is considered ideal for the elution
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buffer.
Procedure: 0.2 g of boronate affigel (Biorad) was hydrated in 5 mL of
TE buffer (10 mM Tris HCl pH 8.0, 1 mM EDTA) and packed in 1 X 4 cm column.
The column was equilibrated using 5 mL of 1 M TEABC pH 9.5 at 4 oC. An
ethanol precipitation was done to 200 µL NTPαSe (20 mM) sample using 600 µL
ethanol, 20 µL 3 M NaCl and 20 µL 1M DTT before the NTPαSe was loaded on
column . The NTPαSe was then redissolved in 1 mL, 1M TEABC buffer, applied
to the column and incubated for 15 mins at 4 oC. Afterwards, washing buffer (1 M
TEABC, pH 9.5, 4 oC) was added. Flow through was collected by 0.5 mL per
tube. Fractions were collected until the maximum absorbance value dropped
below 0.01 as determined by UV. Maximum absorbance values are as follows:
ATPαSe-259nm, UTPαSe-262 nm, GTPαSe-252 nm, CTPαSe-271 nm. Elution
was done using the elution buffer (0.05% acetic acid pH 4.5) and fractions were
collected by 0.5 mL per tube. The tubes were labelled as E1, E2, and so on
depending on the fraction collected. All working buffers were kept on ice during
the procedure.

DNA quantification was done by UV spectrometer and the

absorbance values noted and concentrations calculated.

Analytical HPLC

analysis was performed to determine the quality of purified NTPαSe.
After the purified NTPαSes were eluted from the column, they were
neutralized with 10 µL of TEABC buffer and NaCl/ethanol precipitated. The
sample volume was around 500 μL. 10 μL of 1 M DTT, 50 μL of 3 M NaCl, and
1500 μL of ethanol were added and stored at -80 °C for 30 mins followed by
centrifugation at 14k RPM for 10 mins. The concentration of all NTPαSes was
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adjusted to 20 mM, which was used as 10X solution in transcription reactions.
The HPLC programs for analyzing NTPαSe eluted from the boronate
column: NTPαSe was eluted using a combination of two solvents at varying
proportions: buffer A (20 mM TEAAc in water) and buffer B (20 mM TEAAc, 50%
water, 50% ethanol). The HPLC program for UTPαSe: 20 min 12.5% acetonitrile
with 20 mM TEA·Ac buffer (pH 7) eluted at 1 mL/min. HPLC program for ATPαSe,
and GTPαSe: 20 min 22.5% ethanol with 20 mM TEA·Ac buffer (pH 7) eluted at 1
mL/min. CTPαSe was 20 min 20% ethanol with 20 mM TEA·Ac buffer (pH 7)
eluted at 1 mL/min.

2.2.2 DNA template preparation for RNA transcription
To transcribe RNA, beside the preparation of NTPαSe substrates, the
DNA template must be prepared. Three types of DNA templates, plasmid, PCR
and synthetic DNA templates were used to test for NTPαSe transcription. Based
on the target RNA requirement, different DNA templates can be chosen for
transcription.
For the plasmid template (Figure 2.6 A), the RNA gene was inserted
into pUC19 plasmid with T7 RNA polymerase promoter sequence.

Because

there is no special mark to make T7 RNA polymerase stop at certain point during
transcription, a restriction site (like EcoR I) has to be inserted at the end of the
RNA gene. After the plasmid was purified from E.coli, the plasmid has to be
linearized by restriction endonuclease before it can be used as RNA transcription
template.
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For the PCR dsDNA template (Figure 2.6B) preparation, the template
for PCR could be plasmid, or synthetic DNA.

Advantages of PCR dsDNA

template for RNA transcription are that there is neither a specific sequence
requirement nor length limit for the target RNA molecule. After the PCR reaction
and spin column purification, the PCR product can be directly used for RNA
transcription.
NgoMIV

RNA gene

EcorR I

A. Plasmid dsDNA
T7 RNAP
promotor
Example of plasmid (pUC19, Amp+) inserted region for RNA transcription

RNA gene

B. PCR dsDNA
T7 RNAP
promotor

C. ssDNA template

21.1

RNA

T7 RNAP
promotor

Figure 2.6. Illustration of DNA templates. A: plasmid (pUC19, Amp+) inserted
region for RNA transcription; B: PCR dsDNA template; C: synthetic ssDNA
template.
Another choice for DNA template is synthetic template (Figure 2.6C). In
general, although T7 RNA polymerase works better on dsDNA template,
considering the expense and preparation time, ssDNA is a good option if it is
possible. The ssDNA template is usually prepared as illustrated in Figure 2.6C, a
full length ssDNA template strand and a 21mer promoter strand. There is no
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sequence requirement for the template but there is length limit for synthetic
template (<100 nt). Due to the length limit, synthetic ssDNA template can not be
used directly for these long RNAs. However, synthetic ssDNA template is a very
convenient and economical way for template preparation of short RNAs, like
siRNA.

2.2.2.1. Purification of ssDNA template synthesized by solid phase DNA
synthesizer
DNA single stranded template, prepared by DNA synthesizer, was
deprotected by concentrated ammonium hydroxide at 55 oC over night. DNA in
the supernatant was precipitated by nine volume of n-butanol, redissolved in
water and purified through the appropriate percentage of denature PAGE. The
DNA band on gel, visualized by UV shadowing, was cut and crushed. Gel debris
was soaked with two volumes of water overnight at RT on tube rotator. Next day,
the soaking solution was centrifuged at 3K rpm for 15 min to separate the gel
debris and liquid supernatant. The supernatant was transferred to a clean tube
and the gel debris was washed by one more volume of water (three times) plus
centrifugation for separation each time. All of the supernatant collected after
centrifugation was combined in a fresh tube and filtered by 0.2 μm nylon syringe
filter (Pall).

An NaCl/ethanol precipitation was performed on the filtered

supernatant (-80 oC for 30 min then centrifuge at 14k rpm for 30 min). The DNA
pellet was redissolved in small amount of water and the concentration was
determined by UV at 260 nm. All of the ssDNA template and PCR primers used
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in this dissertation were also purified by this method.
Table 2.2 Sequences of DNA templates prepared by solid phase DNA synthesizer.
Name

Sequence

21.1

5’-GCGTAATACGACTCACTATAG-3’
3’-CGCATTATGCTGAGTGATATCCGTTGGACTACTCCGGC
TTTCCGGCTTTGCATGT-5’
3’-CGCATTATGCTGAGTGATATCCCTCGGGACAGTGGCCT
ACACGAAAGGCCAGACTACTCAGGCACTCCTGTTTTGTCCCGAGGGC
TTAA-5’

55.27
89.24

2.2.2.2 Plasmid construction for RNA transcription template
a. PCR of inserted fragment (New England Biolabs PCR Kit):
Characteristic PCR reactions (100 μL) were carried out using 1 μL
plasmid template - pWNV (80 ng/mL) or 8 μL ssDNA (10 nM) from solid phase
synthesizer, 10 μL each of forward and reverse primers (10 μM), 10 μL 10 X PCR
standard buffer with Mg2+, 0.4 μL Taq DNA polymerase (5 u/μL), 2 μL 10 mM
dNTP, and the proper amount of water to make a final volume of 100 µL. PCR
started at 94 oC for 2 min, then repeated for 35 following cycles 94 oC (30 sec),
55 oC (30 sec, temperature varied for different sequences. Basically, it was 5 oC
below Tm of primers) and 72 oC (30 sec) and the final extension at 72 oC for 2
min. The PCR product was purified by Qiagen MinElute PCR purification kit
using the manufacturer’s suggested protocol. The product was eluted with 20 μL
of water and checked on a 2% agarose gel.

b. Restriction endonuclease digestion of PCR product:
A typical 20 μL double digestion reaction was performed as follows: 6
μL PCR purified product, 1 μL EcoR I (20 u/ μL) 1 μL NgoMIV(10u/μL), 2 μL 10x
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NEB4 buffer (New England Biolabs restriction endonuclease Buffer

4) and

desired amount of water to make final volume 20 µL. The reaction mixture was
kept at 37 °C for 2 hours. The product was purified by Qiagen MinElute PCR
purification kit using the manufacturer suggested protocol.

The product was

eluted with 20 μL of water and checked on a 2% agarose gel.

Table 2.3. PCR template sequences and primer sequences for plasmid
construction
Name
HHM

Template
PCR
Primers

HHN

Template
PCR
Primers

SL(-)

Template

PCR
Primers

SL(+)

Template

PCR
Primers

Sequence
3’-CGCATTATGCTGAGTGATATCCCTCGGGACAGTGGC
CTACACGAAAGGCCAGACTACTCAGGCACTCCTGTTTT
GTCCCGAGGGCTTAA-5’
PF:5’CGACGCCGGCGCGTAATACGACTCACTATAG-3’
(31nt)
PR:3’ACTCCTGTTTTGTCCCGAGGGCTTAAGTACT-5’
(31nt)
3’-CGCATTATGCTGAGTGATATCCCTCGGGACAGTGGC
CTACACGAAAGGCCAGACTACTCAGGCACTCCTGCTTT
GTCCCGAGGGCTTAA-5’
PF:5’-CGACGCCGGCGCGTAATACGACTCACTATAG-3’
(31nt)
PR:3’-ACTCCTGCTTTGTCCGAGGGCTTAAGTACT5’(31nt)
3’-CGGCCGCGCATTATGCTGAGTGATATCGTCGAGCG
TGGCACAATTAACAACAATTAGGAGTGTTTGTGATGATT
CAAACAGTCGAGTGTGTCCGCTTGATGANCTCTGCTTA
AG -5’
PF: 5’-CGACGCCGGCGCGTAATACGACTCACTATAGCA
GCTCGCACCGTGTTAATT -3’ (51nt)
PR:3’-CGAGTGTGTCCGCTTGATGANCTCTGCTTAAGTG
CAC -5’ (37 nt)
3’-CGGCCGCGCATTATGCTGAGTGATATCTCATCAAGC
GGACACACTCGACTGTTTGAATCATCACAAACACTCCT
AATTGTTGTTAATTGTGCCACGCTCGACCATGGCTTAAG
-5’
PF:5’CGACGCCGGCGCGTAATACGACTCACTATAGAGTA
GTTCGCCTGTGTGAGC -3’ (51nt)
PR:3’-TTAATTGTGCCACGCTCGACCATGGCTTAAGTG
CAC -5’ (36nt)
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c. Plasmid restriction endonuclease digestion and purification:
The obtained pUC19 based plasmids (pSAM) were double digested by
EcoR I and NgoMIV as follows: 7 μL purified pSAM (1.4 μg/μL), 1 μL EcoR I (20
u/ μL)

and 1 μL NgoMIV(10 u/μL), 2 μL 10x NEB4 (New England Biolabs

restriction endonuclease Buffer 4) and proper amount of water to make a final
volume 20 µL. The reaction mixture was kept at 37 °C, 2 h and purified on a
0.6% Agarose gel. Linear plasmid bands, visualized by UV photo illuminator
were cut and purified by Qiagen gel extraction kit using the manufacturer
suggested protocol. The product was eluted by 20 μL of water.

d. Ligation:
Purified, restriction endonuclease digested PCR product and linearized
pHHM were ligated with T4 DNA ligase under the following conditions: 1 µL 10X
T4 DNA ligase buffer, 1 µL T4 DNA ligase, 2 µL linearized pHHM, 2 µL PCR
product and 2 µL water were mixed and kept in 16 oC for 1 hours. The reaction
was stopped by inactivating T4 ligase with heating to 65 oC for 10 min.

e. Transformation (Invitrogen Top10 cell):
Transformation of ligated plasmid was carried out using Invitrogen One
Shot® TOP10 chemically competent E. coli using manufacturer’s suggested
protocol. Ten overnight clones on plate were selected for small scale plasmid
preparation using Qiagen Plasmid Mini kit and sent for sequencing.
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f. Large scale plasmid purification and digestion for RNA transcription
The clone with correctly sequenced plasmid was used for large scale
plasmid purification by Qiagen Plasmid Maxi kit.

Before transcription, the

plasmid was linearized by EcoR I as follows: 25 μL plasmid (1.5 μg/μL), 3 μL
EcoR I (20 u/ μL), 10 μL NEB buffer 4 and proper amount of water to make final
volume 100 µL. The reaction mixture was kept at 37 °C 4 h, and then 65 °C for
20 min to inactivate EcoR I. The product was checked on a 0.6% Agarose gel.
The linear plasmid was isolated by NaCl/ethanol precipitation from digestion
buffer.

20 μL of water was added to redissolve the plasmid.

The plasmid

solution was further desalted by 3K Nanosep centrifugal devices (Pall) at 10K
rpm for 10 min. The desalting procedure was repeated once by adding 20 μL
more water and centrifuging again. Then the plasmid was recovered by 20 μL of
RNase free water

2.2.2.3 dsDNA Template prepared by PCR
a. Klenow extension for making full length long DNA template:
Due to the size limit for the oligonucleotide that could be obtained from
solid phase synthesizer, two fragments of P4-P6 DNA template (a 98mer and a
99mer) were synthesized by solid phase DNA synthesizer for Klenow DNA
polymerization to get full length template.
A 5 μL Klenow extension reaction was performed as following: 0.5 μL
denature PAGE purified 98mer and 99mer (10 μM), 0.2 μL of dNTPs with a
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concentration of 10mM, 0.5 μL of 10X Klenow buffer, 0.2 μL of Klenow DNA
Polymerase (5 U/ μL) and desired amount of water to make a final volume of 5
μL. This reaction was incubated at 37 oC for an hour and checked via Agarose
gel electrophoresis. The Klenow extended full length double stranded product
was purified by 12% denature PAGE.

Table 2.4. Polymerization primer sequences for P4-P6
Name
P4-P6

Sequence

Polymerization primer 1 (99
nt)

Polymerization primer 2 (98
nt)

5’-GCGTAATACGACTCACTATAGGGAATTGCGGGA
AAGGGGTCAACAGCCGTTCAGTACCAAGTCTCAG
GGGAAACTTTGAGATGGCCTTGCAAAGGGTAT-3’
5’-GAACTGCATCCATATCAACAGAAGATCTGTTGAC
TTAGGACTTGGCTGCGTGTTAGGACCATGTCCGT
CAGCTTATTACCATACCCTTTGCAAGGCCA-3’

b. PCR (New England Biolabs PCR Kit):
Characteristic PCR reactions (100 μL) were carried out using 1 μL
plasmid template - pWNV (80 ng/mL) or 8 μL ssDNA (10 nM) from solid phase
synthesizer, 10 μL each of forward and reverse primers (10 μM), 10 μL 10 X PCR
standard buffer with Mg2+, 0.4 μL Taq DNA polymerase (5 u/μL), 2 μL 10 mM
dNTP, and desired amount of water to make a final volume of 100 µL. PCR
started at 94 oC for 2 min, then repeated 35 following cycles 94 oC (30 sec), 55
o

C (30 sec, temperature varied for different sequences). Basically, it was 5 oC

below Tm of primers) and 72 oC (30 sec) and the final extension at 72 oC for 2
min. The PCR product was purified by 3K Nanosep centrifugal devices (Pall) at
10K rpm for 10 min before transcription.

It was reported that with 2’-O-methyl
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modification at the last two nucleotides of 5’ of DNA increased the fidelity of RNA
transcription.[94] Therefore, two types of primers were tested. One set was just a
commonly used native primers; the other set has one primer with 2’-O-methyl
modification at the last two nucleotides of 5’, which was the end of transcription.

Table 2.5. PCR template sequences and primer sequences
Name

Sequence

SL(-)

SL(+)

Template

3’-GCGCATTATGCTGAGTGATATCGTCGAGCGTGGC
ACAATTAACAACAATTAGGAGTGTTTGTGATGATTCA
AACAGTCGAGTGTGTCCGCTTGATGA -5’

PCR
Primers

P2: 3’CGAGTGTGTCCGCTTGATGmAm5’ (21nt)
21.15’-GCGTAATACGACTCACTATAG-3’ (21nt)

Template

3’-GCGCATTATGCTGAGTGATATCTCATCAAGCGGAC
ACACTCGACTGTTTGAATCATCACAAACACTCCTAAT
TGTTGTTAATTGTGCCACGCTCGAC -5’

PCR
Primers

P2: 3’TTAATTGTGCCACGCTCGAmCm5’ (21nt)
21.15’-GCGTAATACGACTCACTATAG-3’ (21nt)

P4-P6 Template

3’-CGCATTATGCTGAGTGATATCCCTTAACGCCCTTT
CCCCAGTTGTCGGCAAGTCATGGTTCAGAGTCCCCT
TTGAAACTCTACCGGAACGTTTCCCATACCATTATTC
GACTGCCTGTACCAGGATTGTGCGTCGGTTCAGGAT
TCAGTTGTCTAGAAGACAACTATACCTACGTCAAG-5’

P4-P6 PCR Primers

P2: 5’-GmAmACTGCATCCATATCA ACAG-3’ (21nt)
21.15’-GCGTAATACGACTCACTATAG-3’ (21nt)

2.2.3

Phosphoroselenoate

modified

RNA

(PSe-RNA)

transcription

with

radioactive label
RNA transcribed with radioactive labeling was performed according to
the protocol from the manufacturer (Epicentre T7 RNA polymerase, T7905K) for
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1 h at 37 oC. Each time one type of 10 mM NTPαSe was used to substitute one
type of normal 10 mM NTP solution in protocol (for example, to ATPαSe I tube,
ATPαSe I, CTP, GTP and UTP were added). NTP sample was labeled both by
ATP [α-32P] and CTP [α-32P]. Different types of templates were tested in the
transcription reaction. A typical 10 µL reaction was performed under the final
condition of 1 µM ssDNA template and top promoter strand or 50 ng/µL plasmid
or 6 ng/µL dsDNA PCR template, 0.5 mM NTP or NTPαSe, 10 mM DTT, 1 µL of
10 X Epicentre T7 RNA transcription buffer, 1 µL of Epicentre T7 RNA
polymerase and desired amount of RNase-free water to add volume up to 10 µL.
ATPαSe and GTPαSe samples were labeled by CTP[α-32P], and CTPαSe and
UTPαSe samples were labeled by ATP[α-32P]. The transcription reaction was
quenched by adding equal volume of loading dye containing EDTA (100 mM).
The transcription result was determined by 15% denature PAGE gel by exposure
to film.

2.2.4 PSe-RNA transcription for large scale RNA preparation
Hammerhead ribozyme as an example:
Mutant hammerhead ribozyme (HHM) transcripts (500 µL) were
prepared according to the protocol of the manufacturer (Epicentre T7 flash
transcription kit). The reaction was also includeing 0.1 u/μL phosphatase and 2
mM MnCl2 and the reaction was incubated for 2 h at 37 oC. 100 mM NTPαSe
was used to substitute normal 100 mM NTP from the kit each time. A typical 10
µL reaction was performed under the final condition of 1.5 µM ssDNA template
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and top promoter strand, or 150 ng/µL plasmid, or 50 ng/µL dsDNA PCR
template, 9 mM ATP, 9 mM CTP, 9 mM GTP and 9 mM UTP (when one type of
NTPαSe was used, the corresponding NTP was not added to the transcription
mixture), 10 mM DTT, 0.008 unit pyrophosphatase, 2 mM MnCl2, 1 µL of 10 X
Epicentre T7 RNA transcription buffer, 1 µL of Epicentre T7 RNA polymerase and
proper amount of RNase-free water to add volume up to 10 µL.

After

transcription incubation, 10 µL (10 u) Epicentre DNase I was added at 37 oC for
15 min to remove DNA template.

After 37 oC incubation was finished, an

NaCl/ethanol precipitation was performed (14K RPM, 10 min) to remove
enzymes, short RNA fragments and NTP. RNA pellet was redissolved in 200 µL
water.

2.2.5 Purification of PSe-RNA
2.2.5.1 Gel purification of PSe-RNA
PSe-RNA

was

purified

by

denaturing

polyacrylamide

gel

electrophoresis (PAGE). RNA from transcription was mixed with gel loading dye
(1:1 ratio) that contained 8 M urea. The percentage of denaturing PAGE used for
RNA purification was P4-P6 (9%), hammerhead ribozyme (12%), SL RNA (12%)
and siRNA (19%). After the gel was finished, one glass plate was lifted and a
plastic wrap was placed on PAGE gel. Then a TLC plate was placed on the top of
the plastic wrap. The whole plates and gel set were flipped over with the glass
plate on the top. The PAGE gel was carefully separated from the glass plate with
a spatula. The RNA band on gel was visualized by UV shadowing. The RNA
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band was cut from the gel, transferred to a clean tube and crushed by a RNasefree spatula (All of the solutions used after this step, including RNase-free water,
ethanol, 3M NaCl and so on, were filtered by 0.2 µm nylon membrane filter. For
PSe-RNA purification, 20 mM DTT was added to all RNase-free water used in the
purification steps to dissolve the PSe-RNA). RNase-free water (2 gel volume)
was added to the crushed gel placed in a clean tube for soaking. After soaking
for 4 h at 4 oC with rotation, the gel soaking solution was centrifuged (3K rpm, 10
min, at 4 oC) to remove gel fragments. The supernatant was transferred to a
fresh tube and RNase-free water (one more gel volume) was added to the gel for
washing. The solution was centrifuged again (3K rpm, 10 min, at 4 oC) and the
supernatant was combined with the previous supernatant. This washing step was
repeated two more times. All of the supernatant was collected and filtered
through 0.2 μm nylon syringe filter to a high speed centrifuge tube. NaCl/ethanol
precipitation was then performed to pellet the RNA out of the solution. A typical
ethanol precipitation started with adding 1/10 volume of 3 M NaCl, 3 volume of
ethanol and 10 mM DTT and mixed well. The mixture was left in -80 oC for 30
min and centrifuged at 14K rpm (4 oC) for 30 min.

The RNA pellet was

redissolved in water and desalted by 10K Nanosep centrifugal device (Pall) at 8K
rpm for 10 min.

2.2.5.2 FPLC purification of PSe-RNA
RNA pellet from transcription was redissolved in 100 µL water. PSeRNA was further purified by GE AKTA FPLC system using HiTrap Q anion
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exchange column applying a salt gradient from 0.3 M NaCl to 1 M NaCl. Ethanol
precipitation was then performed to pellet the RNA out of the solution. A typical
NaCl/ethanol precipitation started with adding 1/10 volume of 3 M NaCl, 3 volume
of ethanol and 10 mM DTT and mixed well. The mixture was left in -80 oC for 30
min and centrifuged at 14K rpm (4 oC) for 30 min.

The RNA pellet was

redissolved in water and desalted by 10K Nanosep centrifugal devices (Pall) at
8K rpm for 10 min.

2.2.6 Stability studies of PSe-RNA.
ATPαSe and dTSeT were loaded on the gel with the same protocol as
the large scale RNA purification and recovered from 12.5% denaturing
polyacrylamide gel. ATPαSe and dTSeT bands were visualized by UV shadowing.
The ATPαSe and dTSeT bands cut from the gel were soaked in water overnight
then the solution was centrifuged to remove gel fragments. The supernatant was
collected and filtered with 0.2 μm syringe filter.

The filtered solutions were

analyzed in reverse phase HPLC for components by comparing with standard
samples.

2.2.7 Crystallization of PSe-RNA
Hammerhead ribozyme:
RNA was annealed in the following condition: 1 mM RNA was heated
to 95 oC for 2 min with 10 mM Na-cacodylate pH 6.5 and 1mM spermine, and
cool down to room temperature on heating block.
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Crystallization of hammerhead ribozyme was tested using hanging
drop method in a buffer containing 0.5 mM RNA, 28 mM MgCl2, 18.9 mM
spermine HCl, 35 mM Na-cacodylate pH 6.5, and 6% polyethylene 400.
Reservoir solution is 0.08 M MgCl2, 18 mM spermine HCl, 0.1 M Na-cacodylate
pH 6.5, and 18% polyethylene 400

[95]

.

More HHM crystallization conditions

were screened by nucleic acid sparse matrix (Natrix, Hampton) using hanging
drop method.

P4-P6 domain of group I intron:
RNA was annealed in the following condition: 3.5 mg/mL RNA was
heated 50 oC for 5 min with 5 mM MgCl2, 10 mM NaCl, 5 mM HEPES, pH 6.5.
The solution was cooled to RT on the heating block and MgCl2 concentration was
adjusted to 25 mM after that. [91]
Crystallization was tried for P4-P6 RNA by mixing the annealed RNA
solution with reservoir solution (21% MPD, 50 mM sodium cacodylic acid, pH 6.5,
0.37 mM Spermine) at 2:1, 1:1 and 1:2 ratios using hanging drop method. [91]

2.3 Results
2.3.1 Synthesis, characterization and purification of nucleosides 5’-(alpha-Pseleno) triphosphates
NTPαSes were successfully synthesized without any protective group
on nucleoside and purified by reverse phase HPLC (RP-HPLC). This synthesis
was developed from Ludwig’s and Stawinski’s methods.[92-93] For the first time, all
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eight types of NTPαSe diastereomers were fully characterized by mass
spectrometry, reverse phase HPLC, 1H,

13

C and

31

P NMR (Table 2.6-2.9 and

Figure 2.7).
The RP-HPLC profiles of crude products indicated a dominant
preference for 5’ triphosphates products (results not shown). Based on previous
research results,[96] NTPαSe peak 1 (NTPαSe I) from HPLC profile (Figure 2.7)
was assigned as Sp and NTPαSe peak 2 (NTPαSe II) was assigned as Rp. The
conformation needs to be further confirmed.
The NTPαSe purified by boronate column was a diastereomer mixture
(Figure 2.8-2.11). The UV profiles of all washing and elution fragments of
NTPαSes from boronate column were checked with chromatography as shown in
(Figure 2.8-2.11. left figures). The fragments with high absorption at Max
wavelength of individual nucleotides were collected, combined and ethanol
precipitated. The purified diastereomer mixtures were re-injected into HPLC to
compare with standard samples. The collected fragments were confirmed to
contain two NTPαSe diastereomers without significant oxidation to native NTPs
(Figure

2.8-2.11.

right

figures).

The

RNA

transcription

with

NTPαSe

diastereomers mixture was successful (Figure 2.15). The hammerhead ribozyme
mutant (HHM) was transcribed with all four types of NTPαSe diastereomer
mixtures.

55

2.3.1.1 Synthesis yield, MS and NMR of nucleosides 5’-(alpha-P- seleno)
triphosphates
Table 2.6 NTPαSe ESI-MS and yield
NTPαSe

a

ATPαSe I
ATPαSe II
CTPαSe I
CTPαSe II
GTPαSe I
GTPαSe II
UTPαSe I
UTPαSe II

Molecular Formula

calcd. [M]-

C9H15N2O14P3Se

546.8901

C9H16N3O13P3Se

545.8983

C10H16N5O12P3Se

569.9174

C10H16N5O13P3Se

585.9044

observed [M]546.8848
546.8818
545.8989
545.8972
569.9082
569.9077
585.9043
585.9052

%yielda
32
46
44
67

Yield calculated in percentage by UV

Table 2.7. 1H-NMR (400 MHz) Chemical Shifts (ppm) of NTPαSe in D2O
NTPαSe

H8

H2

ATPαSe I
ATPαSe II
CTPαSe I
CTPαSe II
GTPαSe I
GTPαSe II
UTPαSe I
UTPαSe II

8.64
8.55

8.16
8.16

H6

H5

8.01
7.96

6.08
6.07

8.05
7.96

6.01
5.93

8.12
8.19

H1’

H2’

H3’

H4’

H5’

6.06
6.06
5.91
5.91
5.85
5.85
5.89
5.88

4.71
4.66
4.75
4.75
4.74
4.75
4.75
4.75

4.56
4.56
4.66
4.66
4.65
4.65
4.65
4.65

4.33
4.36
4.32
4.33
4.55
4.51
4.39
4.40

4.28-4.18
4.27-4.19
4.25-4.22
4.26-4.21
4.31-4.20
4.30-4.21
4.34-4.24
4.35-4.23

Table 2.8.13C-NMR (100 MHz) Chemical Shifts (ppm) of NTPαSe in D2O
NTPαSe

C4

C2

C6

C8

C5

C4’

C1’

C3’

C2’

C5’

ATPαSe I
ATPαSe II
CTPαSe I
CTPαSe II
GTPαSe I
GTPαSe II
UTPαSe I
UTPαSe II

149.14
149.12
166.17
165.99
151.82
151.71
166.31
166.33

152.79
152.78
157.80
157.33
153.96
153.93
151.92
151.92

155.57
155.57
142.03
141.77
158.91
158.68
142.13
142.98

140.39
140.14

118.57
118.50
96.78
96.63
116.10
115.83
102.70
102.77

86.70
86.72
89.02
88.92
86.69
86.66
88.13
88.15

83.80
83.79
82.51
82.53
83.76
83.66
83.10
83.21

74.28
74.33
74.20
73.90
73.66
73.77
73.69
73.75

70.40
70.45
69.40
69.30
70.69
70.57
69.63
69.58

65.05
65.78
64.43
65.13
65.39
65.76
64.64
65.46

138.04
137.69
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Table 2.9.31P-NMR (161.97 MHz) Chemical Shifts (ppm) of NTPαSe in D2O
NTPαSe

αP

γP

ßP

Jα,ß(Hz)

Jß, γ(Hz)

ATPαSe I
ATPαSe II
CTPαSe I
CTPαSe II
GTPαSe I
GTPαSe II
UTPαSe I
UTPαSe II

34.04
33.82
33.59
33.17
33.77
33.09
32.82
33.68

-6.89
-6.16
-9.14
-7.11
-9.54
-6.26
-6.50
-5.63

-22.77
-22.65
-23.97
-23.39
-23.96
-23.12
-23.21
-22.48

32.34
34.01
34.01
30.77
32.39
32.39
29.96
34.02

19.44
19.44
19.44
19.44
19.44
21.06
19.40
19.44
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2.3.1.2 HPLC profiles of nucleosides 5’-(alpha-P- seleno) triphosphates

A.

C.

B.

D.

Figure 2.7. Analytic HPLC profiles of NTP, NTPαSe diastereomer I and
diastereomer II.
A1. ATPαSe I (I, 17.4 min); A2. ATPαSe II (II, 18.0 min); A3. Conjection of ATP
(16.4 min), ATPαSe I (I, 17.4 min) and ATPαSe II (II, 17.8 min).
B1. CTPαSe I (I, 10.5 min); B2. CTPαSe II (II, 11.2 min); B3. Conjection of CTP
(9.1 min), CTPαSe I (I, 10.5 min) and CTPαSe II (II, 11.2 min).
C1. GTPαSe I (I, 11.5 min); C2. GTPαSe II (II, 12.1 min); C3. Conjection of GTP
(10.0 min), GTPαSe I (I, 11.5 min) and GTPαSe II (II, 12.2 min).
D1. UTPαSe I (I, 17.4 min); D2. UTPαSe II (II, 18.0 min); D3. Conjection of UTP
(16.4 min), UTPαSe I (I, 17.4 min) and UTPαSe II (II, 18.0 min)
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2.3.1.3 boronate column purification of nucleosides 5’-(alpha-P- seleno)
triphosphate

2

A.

B.

C.

D.

Figure 2.8.
Left: ATPαSe Boronate column purification. Abs at 259 nm
Tube 1-7 were washed by TEABC buffer, pH 9.5
Tube 8-14 were eluted by 0.05 % acetic acid buffer, pH 4.5
Right: HPLC profiles of ATPαSe from boronate column purification.
A. unpurified.
B. after B-column E3
C. after B-column E4
D co-injection of ATP and ATPαSe purified by boronate column (E3)
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A.

B.

C.

Figure 2.9.
Left: GTPαSe boronate column purification. Abs at 252 nm (0.5 mL per tube)
Tube 1-9 were washed by TEABC buffer, pH 9.5
Tube 10-19 were eluted by 0.05 % acetic acid buffer, pH 4.5
Right: HPLC profiles of GTPαSe from boronate column purification (20 min 45%
ethanol)
A. unpurified.
B. after B-column E4
C. co-injection of ATP and ATPαSe purified by boronate column (E3)
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A.

B.

C.

Figure 2.10.
Left: CTPαSe boronate column purification. Abs at 271 nm
Tube 1-9 were washed by TEABC buffer, pH 9.5
Tube 10-18 were eluted by 0.05 % acetic acid buffer, pH 4.5
Right: HPLC profiles of CTPαSe from boronate column purification.
A. unpurified.
B. after B-column E3
C. co-injection of CTP and CTPαSe purified by boronate column (E3)
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Abs at 262 nm

A.E3

B.E4

C.E5

Figure 2.11.
Left: UTPαSe boronate column purification. Abs at 262 nm
Tube 1-7 were washed by TEABC buffer, pH 9.5
Tube 8-14 were eluted by 0.05 % acetic acid buffer, pH 4.5
Right: HPLC profiles of UTPαSe from boronate column purification.
A. after B-column E3
B. after B-column E4
C. after B-column E5
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2.3.2

Phosphoroselenoate

modified

RNA

(PSe-RNA)

transcription

with

radioactive label
2.3.2.1 NTPαSe purified by HPLC for PSe-RNA transcription with radioactive
label
Both NTPαSe diastereomers were tested for RNA incorporation
through plasmid template, PCR template and ssDNA template (Figure 2.12, 2.13
and 2.14). Only NTPαSe I was recognized by T7 RNA polymerase (Figure 2.12,
2.13 and 2.14). The generation of PSe-RNA (HHM, 69mer RNA) with 15 UTPαSe
I incorporation was confirmed by MALDI-TOF (Figure 2.21).
Two types of hammerhead ribozymes were tested for the incorporation
of NTPαSe (Table 2.1 and Figure 2.2). The wild type hammerhead ribozyme
(HHN), transcribed by native NTPs, could cleave itself under transcription
condition right after it has been transcribed (Figure 2.15, NTP, lane N); while with
single nucleotide mutation GÆA (Table 2.1 and Figure 2.2), major RNA
transcripts from mutant hammerhead ribozyme (HHM), were full length product
(Figure 2.15, NTP, lane M).

Due to the presence of phosphoroselenoate

between C and A at the cleavage site (Figure 2.2), HHN transcribed by ATPαSe I
showed no self-cleavage activity (Figure 2.14, ATPαSe I, lane N); while
substitution of other NTPαSe I (except ATPαSe I) in HHN did not result in any
inhibition on the self-cleavage activity (Figure 2.15). Consistent with our previous
results,[38] the selectively selenium derivatized ribozymes were still active, and
suggested that selenium modifications on non-essential phosphate did not cause
major structural perturbation that would significantly affected the ribozyme activity.
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The inhibited hammerhead ribozyme self-cleavage activity due to ATPαSe I
incorporation (Figure 2.15, ATPαSe, lane N), also supported that the full length
RNA bands in Figure 2.12 were not oxidized native RNA products.
N

A1

A2 A1&2 G1 G2 G1&2 C1 C2 C1&2 U1 U2 U1&2
HHM RNA

Figure 2.12. Enzymatic incorporation of NTPαSe I and II into HHM RNA using
plasmid template. As described in the method 2.2.3, RNA was labeled by ATP [α32

P] and CTP [α-32P].

N

A1

A2

A1&2 G1 G2 G1&2 C1 C2 C1&2 U1 U2

U1&2
SL(-) RNA

Figure 2.13. Enzymatic incorporation of NTPαSe I and II into SL(-) RNA using
double strands DNA templates prepared from PCR. As described in method 2.2.3,
RNA was labeled by ATP [α-32P] and CTP [α-32P].
N

A1

A2

A1&2 G1 G2

G1&2 C1 C2

C1&2

U1

U2

U1&2

55.27 RNA

Figure 2.14. Enzymatic incorporation of NTPαSe I and II into 55.27 RNA using
ssDNA templates prepared from solid phase synthesizer. As described in method
2.2.3, RNA was labeled by ATP [α-32P] and CTP [α-32P].
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Figure 2.15. Transcription of a hammerhead ribozyme mutant (HHM RNA is
represented as M) and wild type (HHN RNA is represented as N) using NTP or
NTPαSe I.

2.3.2.2 Transcription of NTPαSe purified by boronate column for PSe-RNA
transcription with radioactive label
NTPαSe diastereomers purified by boronate column were tested for
transcription of HHM (Figure 2.16). Full length RNA products were obtained for
all four types of NTPαSe diastereomers. The results proved that the boronate
column was able to remove the impurities from NTPαSe synthesis and mixture of
NTPαSe diastereomers could be used for transcription directly.

The boronate

column method could be a convenient way for large scale NTPαSe purification.

NTP

ATPαSe

CTPαSe GTPαSe

UTPαSe

Figure 2.16. Transcription of NTPαSe purified by boronate column (12% PAGE).
All RNA transcripts were labeled by CTP [α-32P].
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2.3.3 Phosphoroselenoate modified RNA (PSe-RNA) transcription for large scale
RNA preparation
For the modified nucleotides incorporation by T7 RNA polymerase, the
transcription condition needs to be tested and optimized to yield maximum PSeRNA. Considering that Mn2+ could give T7 RNA polymerase more flexibility and
Mn2+ has higher affinity to selenium than Mg2+, additional Mn2+ was added to
Epicentre T7 RNA transcription buffer. The appropriate Mn2+ concentration and
transcription time were tested and result is shown in Figure 2.17. With plasmid
template, 2 h transcription and 2 mM additional Mn2+ was the best condition for
UTPαSe incorporation.
The transcriptional yields for hammerhead ribozyme mutant from two
batches of UTPαSe (seU1 and seU2), with half amount of plasmid (1/2 HHM) are
shown in Figure 2.18. There was no difference between two batches of UTPαSe
I (seU1 and seU2, Figure 2.18). Reduced plasmid quantity resulted in significant
decrease in product yield during a 2 h transcription. The best transcription
condition, from the results of optimization experiment is stated in method 2.2.4
PSe-RNA transcription for large scale RNA preparation.
The effect of 2’-O-methyl modification (2’Me) at the last two nucleotides
of 5’ on DNA template was tested in P4-P6 RNA transcription (Figure 2.19).
2’Me modification of the template increased the yield of RNA transcription in both
NTP and UTPαSe1 transcription for about 2.5 fold (Figure 2.19. Right).

The

proper concentration of 2’Me PCR template for large scale RNA transcription was
tested using a protocol for large scale RNA preparation (Figure 2.20). For 2’-O-
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Me PCR template 500 ng/µL working solution was used for large scale RNA
transcription.
The generation of PSe-RNA (HHM, 69mer RNA) with 15 UTPαSe I
incorporation was confirmed by MALDI-TOF (Figure 2.21). The mass native HHM
RNA is shown in Figure 2.22.

2.3.3.1. Optimization for PSe-RNA transcription
NTP
Mn2+ ::
Time:
Template:

0
2
P

UTPαSe
2
2
P

0
2
P

0
4
P

0 0
6 16
P P

UTPαSe
2
2
P

2
4
P

2
6
P

UTPαSe
2 4 4
16 2 4
P P P

4
6
P

NTP UTPαSe
4
16
P

0
2
S

0 (mM)
2 (h)
S

Figure 2.17. Optimization of large scale UTPαSe RNA transcription conditions
using T7 RNA polymerase in 2-16 hours (RNA bands were shown by UV
shadowing). RNA transcript is hammerhead ribozyme mutant (HHM). P: plasmid
template. S: synthetic template.
NTP

SeU1

SeU2 ½ HHM

HHM RNA
1
2
3
4
Figure 2.18. Plasmid template concentration optimization for HHM transcription
condition (RNA bands were showed by UV shadowing). Lane 1-3: final 160 ng/µL.
Lane 4: final 80 ng/µL.
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400
350

P4-P6

300
250
native

200

2'Me

150
100
50
0
NTP

1
Figure 2.19.

SeUTP

2

3

4

Comparison of normal PCR template and 2’-O-methyl modified

PCR template for P4-P6 RNA transcription by NTP and UTPαSeI.
Left: Gel image. All RNA transcripts were labeled by ATP [α-32P]. Lane 1: NTP
with normal PCR DNA template; Lane 2: NTP with 2’-O-methyl modification PCR
DNA template; Lane 3: UTPαSe1 substitution with normal PCR DNA template;
Lane 4: UTPαSe1 substitution with 2’-O-methyl modification PCR DNA template.
Right: quantified data of gel image (Left).
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P4-P6 RNA

Dye

Figure 2.20. Concentration test for P4-P6 2’-O-methyl modification PCR DNA
template. The top concentration label is 10 X working solution of P4-P6 2’-Omethyl modified PCR DNA template. RNA bands from 5 µL transcription were
showed by UV shadowing.
2.3.3.2. MALDI-TOF of PSe-RNA
23,314

Figure

2.21.

MALDI-TOF

of

PSe-U

hammerhead

ribozyme

(C657H814N264O465P68Se15) Cald. [M] 23,144, [M+THAP] 23,312.

(HHM)

Observed

[M+THAP] 23,314. THAP, standing for 2′,4′,6′-Trihydroxyacetophenone (C8H8O4,
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mass 168.04), is a type of MALDI matrix.

Figure 2.22. MALDI-TOF of native hammerhead ribozyme (HHM) calc. [M]
=22,456; observed [M+Na++Spermine] =22,681

2.3.4 Purification of PSe-RNA
The full length PSe-RNA could be purified by denaturing PAGE or
FPLC.

Figure 2.23 and 2.24 showed the RNA bands on denaturing PAGE.

These RNA bands were visualized by UV shadowing. Figure 2.23 compared RNA
SL(-) (plasmid template) transcription yield from all native NTP condition and with
UTPαSe I substitution.

Figure 2.24 showed the transcription yield of

hammerhead ribozyme from synthetic stranded template (89.24) and plasmid
template (HHM and (HHN). The sequence of RNA from 89.24 was the same as
HHM (Table 2.1), while HHN RNA was the wild type self-cleaved hammerhead
ribozyme.
The FPLC profile for purifying PSe-RNA is shown in Figure 2.25. NTP
(Figure 2.25, peak at 1.08 min) was removed in the washing steps of the anion
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exchange column.

PSe-RNA eluted at 10.89 min.

The RNA after anion

exchange column was desalted by size exclusion column and concentrated by
spin column. The RNA purified under these denature conditions was annealed
later to the proper conformation.

2.3.4.1 Gel purification of PSe-RNA
NTP

UTPαSe

Figure 2.23. RNA band of WNV ribosome entry site SL(-) (plasmid template) from
NTP and UTPαSe on denature PAGE.

89.24

HHM HHN

Figure 2.24. RNA transcribed from single stranded 89.27 ssDNA template and
plasmid DNA template HHM (hammerhead ribozyme mutant) and HHN (native
hammerhead ribozyme) on denature PAGE.
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2.3.4.2 FPLC purification of PSe-RNA

Figure 2.25. FPLC anion exchange column purification of PSe-U hammerhead
ribozyme (10.89 min)

2.3.5 Stability studies of PSe-RNA
The stability of PSe-RNA during gel purification process was tested by
a dT-PSe-T dimer. The data from RP-HPLC analysis (Figure 2.26) showed that
ATPαSe, as well as dT-PSe-T, were quite stable in polyacrylamide gel. Only less
than 5% dT-PSe-T dimer converted to native dTT dimer. This suggested that
RNA with selenium incorporation could be purified by ordinary polyacrylamide gel,
and is a quite convenient way for selenium containing RNA purification.
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A.

B.

Figure 2.26. Stability studies of PSe-RNA (A). HPLC profiles of ATP stock
solution, ATP purified from gel, co-injection of ATPαSe purified from gel and
ATPαSe stock solution, ATPαSe stock solution and ATPαSe purified from gel. (B).
HPLC profiles of dTT, co-injection dTT and dTSeT from gel, dTSeT stock solution
and dTSeT from gel.
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2.3.6 Crystallization of PSe-RNA
The hammerhead ribozyme and P4-P6 RNA was tested for crystallization. The
experiment has not been finished.

2.4 Discussion
Nucleotide triphosphates are common biological molecules in all life
forms, and their analogues could have wide scientific and therapeutic
applications.

Phosphorothioate analogues have been used for enzymatic

mechanism, antisense and RNAi studies,[97] which are also potential applications
for phosphoroselenoate analogues. Our new facile synthesis route, separation
method for NTPαSe diastereomers and preparation protocol for PSe-RNA
enabled preparation of PSe-RNA for X-ray crystallography.
The template tests showed that only NTPαSe I could be incorporated
into RNA by T7 RNA polymerase through both ssDNA and dsDNA. Then the
transcribed PSe-RNA was diastereomerically pure, which was different from PSeDNA generated from solid phase synthesis method reported by Egli and coworkers [27].
An ideal nucleic acid heavy atom derivative should be stable during the
X-ray crystallography experimental process, not cause significant structure
perturbation and be site-specifically incorporated into nucleic acid. The selenium
modification at the alpha phosphate position was relatively stable during the RNA
purification step with DTT added as reducing agent. Whether the PSe-RNA is
still stable during crystallization conditions and X-ray radiation condition and
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whether the additional reducing agent can change the crystallization conditions
needs to be further investigated. Another concern is whether there is structure
perturbation on PSe-RNA. Although the short double stranded PSe-DNA did not
show significant structure perturbation,

[27]

the final answer about PSe-RNA

requires crystal structures of PSe-RNA, which are not available now.

A few

questions can be addressed here through the hammerhead cleavage experiment
(Figure 2.15).

The selenium substitution of oxygen at the non-bridging site

between C and A at the cleavage site (Figure 2.15) inhibited hammerhead
ribozyme cleavage reaction, which could be caused by lower selenium affinity to
Mg2+ compared with oxygen, as happened with the phosphorothioate
ribozyme.[44] On the other hand, selenium substitutions of other non-bridging
sites of the hammerhead ribozyme, like in the cases of CTPαSe I, GTPαSe I and
UTPαSe I (Figure 2.15), did not inhibit the ribozyme cleavage activity.

This

indicated that the hammerhead ribozyme could still fold into the active
conformation with selenium substitutions. The inihibition effect may only come
from the atomic change in active site. For the concern about affecting RNA
global folding due to altered metal affinity, phosphate modification site could be
selected and tested, since all four types of NTPαSe are ready to be chosen. This
concern also leads to the discussion of the difficulty in site-specificity for
enzymatic incorporation.

Unlike the low natural abundance of methionine in

proteins (2.2%),[98] there are only four types of nucleic acids. Replacement of any
one of the nucleic acid substrate with selenium modified substrate in transcription
reaciton will result in around 25% nucleic acid substitution, which is much more
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than what is needed for solving the phase problem and may result in unwanted
structure perturbations and difficulties in locating these selenium atoms. To help
solve these problems, a substrate mixture of NTP and NTPαSe can be used to
reduce the amount of selenium incorporation. For even higher requirements on
site specific incorporation, a combination with the T4 RNA ligase method can be
an option. [75]
In summary, we have synthesized and characterized all eight types of
NTPαSe diastereomers. The method described here is a very efficient way for
the synthesis of 5’-(alpha-P-seleno)triphosphates, which does not require any
protective groups on nucleosides and no multiple steps of purification. The
generation of 5’-(alpha-P-seleno)triphosphates was confirmed by MS, 1H,
and

31

13

C

P NMR, and T7 RNA transcription. These NTPαSes were purified through

either RP-HPLC or boronate column method. All RP-HPLC purified NTPαSe I
are good substrates for T7 RNA polymerase, while NTPαSe II are neither
inhibitor nor substrates for T7 RNA polymerase. NTPαSe diastereomers mixture
purified by boronate column could be directly used for RNA transcription (Figure
2.16). The transcription conditions for large scale preparation of PSe-RNA has
been optimized with additional Mn2+ in transcription buffer. Full length PSe-RNA
with multiple selenium modifications was generated, purified by gel or FPLC and
confirmed by mass spectrum. The PSe-RNA was relatively stable under gel
purification conditions. The information in this dissertation would definitely help to
advance studies on ribozyme catalytic mechanism, RNA X-ray crystal structure
and function, and RNA interference
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3.

PHOSPHOROSELENOATE RNA FOR RNA INTERFERENCE STUDIES

3.1 Introduction
RNA interference (RNAi), the post transcriptional gene silencing
(PTGS) induced by double-stranded (dsRNA), is a powerful tool for directed
inhibition of gene expression in scientific research and it also has great potential
for therapeutic applications.

[99]

RNAi can be induced by short (21-23 nt) dsRNA,

known as small interference RNA (siRNA), which will be further processed by
RNA-induced silencing complex (RISC) in cytoplasm.[100]

The antisense strand

(guide strand) in siRNA is complementary to the sequence of target mRNA
molecule. After siRNA has assembled with RISC, RISC unwinds the duplex and
only the antisense strand is loaded in activated RISC. The activated RISC with
antisense strand siRNA will degrade the target mRNA or inhibit the translation of
target mRNA.[101]
There are still several major problems in the application of RNAi for
therapeutic purpose.

[100]

First is target identification; RNA interference works

with mismatches, therefore, one siRNA may have more than one substrate.[102]
Target specificity has to be considered in siRNA design to avoid side effect.
Second, the effective delivery of oligonucleotides to the cell is also a problem.[103104]

Third, the stability of siRNA against nuclease degradation has to be

improved.[105] In primitive organism and plants, siRNA is quite effective. Long
dsRNA can be converted to many 21-23 nt siRNA with some degree of
amplification.

[106]

However, in mammalian cells, long dsRNA could trigger the

interferon reaction[107] and there are lots of nucleases in the serum. Increasing
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the RNase resistance of siRNA is a practical way to elongate the siRNA lifetime
and thus enhance RNAi activity.
A good chemical modification on RNA should increase the RNase
resistance of siRNA without reducing the RNAi effect and being toxic for cells

[108]

.

Thermodynamic stability of modified siRNA has to be checked since that could
also affect target affinity and specificity.[109] Nucleases basically cut the
phosphodiester bond of RNA. Modification of certain phosphodiester linkage on
siRNA is considered to be able to increase the half-life of siRNA in vivo.
Phosphothioate (PS) linkage modification was previous used on antisense
technology to increase the resistance to RNase and also proved able to increase
the siRNA stability.[37,

108]

Phosphoselenoate (PSe) linkage has similar

characteristics as phosphothioate linkage and has also shown RNase resistance;
while due to unavailability of the material; this type of modification has never
been tested for RNAi activity yet.[38]
SiRNA could be prepared through enzymatic and synthetic methods.
[110]

For enzymatic modification, the nucleoside triphosphate with modification has

to be accepted by RNA polymerase.

Our lab developed the method for

enzymatic synthesis of PSe-siRNA using NTPαSe. To test the RNA interference
activity of these PSe-siRNAs, target protein selected was pyruvate kinase type
M2 (PKM2), a nonorganspecific tumor marker and a key regulator in tumor
metabolome.[111] Inhibition of PKM2 in the cell experiment by commercial siRNA
was not efficient due to rapid RNase degradation. SiRNA with more RNase
resistance was desired by study on PKM2.

PSe-RNA had previously
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demonstrated strong RNA resistance,[38] as a result, PSe-siRNA against PKM2
was designed for RNAi activity test.

It was reported that siRNA synthesized by

the most commonly used bacteriophage T7 RNA polymerase with 5’ triphosphate
induced interferon reaction in mammalian cells.

[110]

Therefore, we also tested

the whether 5’ triphosphate of siRNA would induce cell apoptosis.

3.2 Materials and methods
UTPαSe used for siRNA transcription was purified by HPLC. The
detailed synthesis and purification method were stated in chapter one.
Table 3.1. siRNA sequences
Name

Sequence

Antisense(N)

5’-GGUCGCUGGUAAUGGGCGCCUU-3’

Sense (N)

5’-GGCGCCCAUUACCAGCGACCUU-3’

Antisense (Se)

5’-GGseUCGCseUGGseUAAseUGGGCGCCseUseU-3’

Sense (Se)

5’-GGCGCCCAseUseUACCAGCGACCseUseU-3’

3.2.1 siRNA transcription
SiRNA transcription (100 µL) was performed according to manufacturer
protocol (Epicentre T7 flash transcription kit) with extra pyrophosphatase in
reaction buffer for 2 h. 100 mM UTPαSe I (purified by RP-HPLC) was used to
substitute normal 100 mM UTP from the kit.

A typical 100 µL reaction was

performed under the final condition of 1.5 µM ssDNA template and top promoter
strand, 9 mM NTP or NTPαSe I, 10 mM DTT, 0.08 u pyrophosphatase, 10 µL of
10 X Epicentre T7 RNA transcription buffer, 10 µL of Epicentre T7 RNA
polymerase and proper amount of RNase-free water to add volume up to 100 µL.
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After transcription, 20 µL (20 u) DNase I was added at 37 oC for 15 min to
remove DNA template. The product was purified by 19% denature PAGE gel
with same protocol for large scale RNA purification as stated in 2.2.5.1. Ethanol
precipitation was then performed to recover RNA from gel soaking solution.
Pellet was redissolved in 50 µL RNase-free water. The gel purified siRNA was
desalted by 3K centrifugal membrane filter (Pall).
To investigate the 5’ triphosphate effects on RNAi, a set of siRNA was
prepared with additional alkaline phosphatase to remove 5’ phosphate before gel
purification. The alkaline phosphatase reaction was performed as following:
siRNA strand transcribed from 100 µL reaction after ethanol precipitation was redissolved by 1X alkaline phosphatase buffer with 50 u alkaline phosphatase. The
mixture was left in 37 oC water bath for 1 h and the reaction was stopped by
adding equal volume of gel loading dye.

This set of siRNA without 5’

triphosphate was labeled as siRNA 1 to 4. The other set of siRNA with 5’
triphosphate was labeled as siRNA A to D.
The siRNA sample purified by gel and desalted by 3K centrifugal
membrane filter, was performed one more ammonium salt ethanol precipitation
for MALDI-TOF analysis.

The siRNA sample was sent to Scripps Center for

Mass Spectrometry for MALDI-TOF.

3.2.2 siRNA duplex preparation
Two complementary strands of PSe-siRNA (50 µM each) were
annealed in 800 µL 2.5 X PBS buffer (10X phosphate buffered saline, pH 7.4, 10
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mM KH2PO4, 1550 mM NaCl, 30 mM Na2HPO4). The siRNA samples for Melting
temperature (Tm) studies was annealed with additional 20 mM borane in
tetrahydrofuran (THF, Sigma 176192).

The siRNA samples for RNAi activity

study was annealed with additional 100 mM DTT in annealing buffer. Annealing
of RNA was performed on a heating block by holding at 95 oC for 5 min then
slowly cooled down to room temperature in 2 h. The annealed siRNA duplex was
purified by 10K membrane centrifugal filter and redissolved in 20 µL water.
There are eight types of annealed siRNA. The set without 5’
triphosphate was labeled as siRNA 1 to 4. The other set of siRNA with 5’
triphosphate was labeled as siRNA A to D. The PSe-siRNA 1 represents for
antisense(N)+sense(N)

duplex;

PSe-siRNA

2

represents

for

antisense(N)+sense(Se) duplex; PSe-siRNA 3 presents for antisense(Se)+sense
(N) duplex; PSe-siRNA 4 represents for antisense(Se)+sense(Se) duplex. The
PSe-siRNA A represents for antisense(N-3P)+sense(N-3p) duplex; PSe-siRNA B
represents for antisense(N-3P)+sense(Se-3p) duplex; PSe-siRNA C represents
for antisense(Se-3P)+sense(N-3p)

duplex; PSe-siRNA D represents for

antisense(Se-3P)+sense(Se-3p) duplex.

3.2.3 siRNA duplex Tm study
The melting temperature (Tm) sample was prepared by mixing 20 µL
annealed siRNA duplex solution with 780 µL Tm buffer (pH 7.0, 0.1 M
diammonium citrate). Sample was overlaid with 20 µL light mineral oil to prevent
evaporation at higher temperature. The Tm of PSe-siRNA was performed by
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measuring the change in absorbance at 260 nm using Cary 300 Bio UV/Vis
spectrophotometer thermal software from 14 oC to 98 oC and from 98 oC to 14 oC
in 2 oC increments with an equilibration time of 0.2 min at each temperature.

3.2.4 siRNA RNAi activity study
Cell Culture
SW480 cells were grown in L-15 medium (Leibovitz) supplemented
with 10% fetal bovine serum at 37°C in a CO2-free incubator. Cells were subcultured in a ratio of 1:4 or 1:6 twice weekly.

siRNA transfection and cell viability assay
SW480 cells were grown in a density of 30% confluence in 6-well
plates and transiently transfected with 200 pmole small interfering RNA (siRNA)
using Lipofectamine™ RNAiMAX (Invitrogen). The viability of transfected cells
was analyzed by Trypan Blue (Sigma) staining method 48 h after siRNA
transfection. By the time of viability assay, the cells were suspended using
trypsin-EDTA (Invitrogen). The cells were then washed and re-suspended by icecold PBS buffer. The suspended cells were mixed with 0.4% Trypan Blue in a
ratio of 1:1 (50 µl+ 50 µl). After 5 min incubation, the cells were counted using
hemocytometer under light microscope. The transparent cells were taken as the
live cells and the dark blue cells were the dead cells. The non-targeted siRNA
and wild type PKM2 siRNA were used in this experiment as a control.
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Western Blot
Protein samples were loaded and separated in a SDS polyacrylamide
gel. The electrophoresed proteins in gel were transferred onto a nitrocellulose
membrane (Millipore) and the membrane was incubated in blocking solution (5%
BSA/TBST (20mM Tris-HCl pH7.4, 150mM NaCl, 0.1% Tween-20)) for 1 hour at
room temperature. The membrane was washed with washing buffer (TBST) for 3
times, 5 min for each and then incubated with rabbit anti-human PKM2
antibodies which were diluted 1:1000 in blocking buffer for 2 hours at room
temperature. The probed membrane was washed 3 times with washing buffer, 5
min for each, at room temperature and incubated with an appropriate secondary
reagent such as goat anti-rabbit IgG-HRP at 1:5000 dilution in blocking buffer for
1 hour at room temperature. The membrane was then washed and the signal
was detected with chemiluminescence reagents

3.3 Results
3.3.1 Characterization of PSe-siRNA
3.3.1.1 MALDI-TOF of siRNA transcript
The mass of native siRNA and PSe-siRNA are showed in Figure 3.1 (A.
antisense and B. Sense) and Table 3.2. These results confirmed the generation
of full length RNA transcripts with six selenium atoms in antisense strand and
four selenium atoms in sense strand.
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Table 3.2. Summary of siRNA MALDI-TOF MS.
Name

Composition

calc.[M]

obs.[M]

Antisense (N)

A2C5G9U6

[M]=7305

[M]=7305

+

Antisense (Se)

A2C5G9Use6

[M+H ]=7684

[M+H+]=7687

Sense (N)

A4C9G5U4

[M+H+]=7189

[M+H+]=7191

Sense (Se)

A4C9G5Use4

[M+H+]=7445
[M+H++Na++K+]=7506

[M+H+]=7447
[M+H++Na++K+]=7508

3.3.1.2 PSe-siRNA Tm study
The experiment on siRNA duplex indicated that the selenium
modification on phosphate did not interrupt RNA duplex base-pairing. There was
no significant difference on the melting temperature (Tm) (Table 3.3) of native
siRNA (Figure 3.2. A), siRNA with single strand selenium modification (Figure 3.2.
B and C), and siRNA with double strands selenium modification (Figure 3.2.D)

Table 3.3.Summary of siRNA Tm result.
siRNA duplex

Tm result

Antisense (N)+Sense(N)

88.25±0.48 oC

Antisense (N)+Sense(Se)

87.26±0.51 oC

Antisense (Se)+Sense(N)

89.27±0.45 oC

Antisense (Se)+Sense(Se)

89.39±0.60 oC
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Anti (N)

Anti (Se)

A.

B.

Sense (N)
7191

Sense (Se)
7447 7508

Figure 3.1.MALDI-TOF Mass-spectrum of siRNA antisense strand (A) and sense
strand (B)
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A.

B.

C.
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D.

Figure 3.2. PSe-siRNA Tm study. A. Antisense (N)+Sense(N);B. Antisense
(N)+Sense(Se); C. Antisense (Se)+Sense(N); D. Antisense (Se)+Sense(Se)

3.3.2 PSe-siRNA interference activity
3.3.2.1 siRNA interference activity and cell growth of siRNAs with triphosphate on
5’annealed with borane in tetrahydrofuran.
The first RNAi test was done with siRNAs with triphosphate on 5’ and
these siRNA was annealed with borane in tetrahydrofuran. siRNA with double
strand selenium modifications (Figure 3.3. Lane 3) showed highest RNAi effect.
The siRNA with antisense selenium modification (Figure 3.3. Lane 2) had higher
activity than no selenium modification (Figure 3.3. Lane 1). The results of native
siRNA A and commercial PKM2 siRNA was comparable (Figure 3.3. Lane 1 and
4). siRNA with double strand selenium modifications showed higher cell death
number compared with other single strand modification and native siRNA (Figure
3.4 A and B).

It was suspected either the 5’ triphosphate of siRNA duplex,

selenium or the borane used for annealing played a role on the increased cell

87

growth inhibition.

1
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3

4

5

6

IB: PKM2

IB: Actin

Figure 3.3. PSe-siRNA RNA knocked down PKM2 (48h). PKM2 (pyruvate kinase
type M2). The siRNAs were annealed with borane in tetrahydrofuran. These
siRNAs have triphosphate on 5’. 1. PSe-siRNA A; 2. PSe-siRNA C 3. PSe-siRNA
D; 4. Commercial native siRNA; 5. Smart top: mix of siRNA targeting PKM2; 6. no
siRNA control
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Figure 3.4.A. Se-RNA treatment inhibits cell growth (24h). PKM2 (pyruvate
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kinase type M2). The siRNAs were annealed with borane in tetrahydrofuran with
triphosphate on 5’.

1: PSe-siRNA A 2: PSe-siRNA C; 3: PSe-siRNA 4;

Commercial siRNA; 5: Commercial siRNA with difference sequence targeting
same protein. 6: no siRNA control.

1.PSe-siRNAA

4. Commeiral siRNA

2. PSe-siRNA C

3. PSe-siRNA D

5.Smart top mix of siRNA targeting PKM

6. no siRNA

Figure 3.4.B. Se-RNA treatment inhibits cell growth (48h). PKM2 (pyruvate
kinase type M2). The siRNAs were annealed with borane in tetrahydrofuran.
These siRNAs have triphosphate on 5’.

3.3.3.2: siRNA interference activity and cell growth of siRNAs without
triphosphate on 5’.annealed by 100 mM DTT.
Considering the borane and tetrahydrofuran leftover in annealing
solution may affect the cell growth, another type of reducing agent DTT was used
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in later annealing processes. RNAi activity from siRNA without 5’ triphosphate
was showed in Figure 3.5. Native siRNA 1, single strand modified siRNA 2 and 3
had similar RNAi effect as commercial siRNA (Figure 3.5. Lane 6).

PKM2

expression was strongly inhibited by double strand selenium modified siRNA 4
(Figure 3.5. Lane 4). There was no significant difference on cell growth for all
samples (Figure 3.6). The double strand selenium modified siRNA 4 had best
RNAi effect and was not toxic to cell (Figure 3.5. Lane 4 and Figure 3.6. Lane 4).
1

2

3

4

5

6

7

IB:PKM2
IB: Actin -

Figure 3.5. PSe-siRNA RNA knocked down PKM2 (48h). PKM2 (pyruvate kinase
type M2). The siRNAs were annealed with 100 mM DTT. These siRNAs do not
have triphosphate on 5’. 1. siRNA 1; 2. siRNA 2; 3. siRNA 3; 4. siRNA 4; 5. no
siRNA control ; 6. Commercial normal siRNA; 7. Smart top: mix of siRNA
targeting PKM2
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Figure 3.6. Se-RNA treatment does not inhibit cell growth (48h). PKM2 (pyruvate
kinase type M2). The siRNAs were annealed with 100 mM DTT. These siRNAs
do not have triphosphate on 5’. 1. siRNA 1; 2. siRNA 2; 3. siRNA 3; 4. siRNA 4; 5.
No siRNA control; 6. Commercial normal siRNA;

3.3.3.3: siRNA interference activity and cell growth of siRNAs with triphosphate
on 5’.annealed with DTT.
This RNAi test was done with siRNAs with triphosphate on 5’ and
these siRNA was annealed with 100 mM additional DTT in buffer. Double strand
modified siRNA (Figure 3.7. Lane 6) showed higher RNAi effect. The siRNA with
antisense strand selenium modification (Figure 3.7. Lane 5) had higher activity
than sense strand selenium modification (Figure 3.7. Lane 4). The result of native
siRNA A and commercial PKM2 siRNA was comparable (Figure 3.7. Lane 3 and
2). siRNA with double strand selenium modifications showed higher cell death
number compared with other single strand modification and no modification
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(Figure 3.9). siRNA A (Figure 3.9. Lane 3) did not show significant difference on
cell death rate compared with commercial siRNA (Figure 3.9. Lane 2).

1

2

3

4

5

6

Figure 3.7. Western blot analysis of siRNA (A-D) knockdown of PKM2 in SW620
cells. The siRNAs were annealed with DTT. These siRNAs have triphosphate on
5’. 1. No siRNA control; 2. Commercial normal siRNA; 3. siRNA A; 4. siRNA B; 5.
siRNA C; 6. siRNA D;
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Figure 3.8. PKM2 inhibition by siRNA (A-D) showed as column. 1. No siRNA
control; 2. Commercial normal siRNA; 3. siRNA A; 4. siRNA B; 5. siRNA C; 6.
siRNA D.

92

40
35
30
25
20

Series1

15
10
5
0

1
Control

2
SiRNA

3
Se-A

4
Se-B

5
Se-C

6
Se-D

Figure 3.9. The number of dead cells in siRNA (A-D) knockdown of PKM2 in
SW620 cells. 1. No siRNA control; 2. Commercial normal siRNA; 3. siRNA A; 4.
siRNA B; 5. siRNA C; 6. siRNA D.

3.3.3.4 siRNA interference activity and cell growth of all eight types of siRNA
duplex annealed with DTT.
To investigate the effect of 5’ triphosphate on RNAi, eight types of
siRNA were prepared and tested simultaneously. The siRNA 1-4 showed higher
RNAi activity than siRNA A-D (Figure 3.10). The loading control of these results
was not consistent; therefore the results were not conclusive.

There was no

significant difference on the average living cell numbers between the two groups
(Figure 3.11). An additional experiment was repeated with the same groups of
siRNA and conditions for cell viability (Figure 3.12). There was no significant
difference between the group siRNA A-D (with 5’ triphosphate) and siRNA 1-4
(without 5’ triphosphate).
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PKM2
Loading
control
GAPDH

Non CS A B

C

D 1

2

3

4

Figure 3.10. PKM2 inhibition with eight types of siRNAs. Non: no siRNA control;
CS: Commercial siRNA; A: PSe-siRNA A; B: PSe-siRNA B; C: PSe-siRNA C; D:
PSe-siRNA D; 1: PSe-siRNA 1; 2: PSe-siRNA 2; 3: PSe-siRNA 3; 4: PSe-siRNA
4.

Figure 3.11. The numbers live cells in eight types of siRNA treatment. nt: no
siRNA control; PKM2: Commercial siRNA; A: PSe-siRNA A; B: PSe-siRNA B; C:
PSe-siRNA C; D: PSe-siRNA D; 1: PSe-siRNA 1; 2: PSe-siRNA 2; 3: PSe-siRNA
3; 4: PSe-siRNA 4.
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Figure 3.12. SW240 cell viability in eight types of siRNA treatment. nt: no siRNA
control; PKM2: Commercial siRNA; A: PSe-siRNA A; B: PSe-siRNA B; C: PSesiRNA C; D: PSe-siRNA D; 1: PSe-siRNA 1; 2: PSe-siRNA 2; 3: PSe-siRNA 3; 4:
PSe-siRNA 4. Two repeats experiment were done. Test 1 in blue. Test 2 in red.

3.4 Discussion
Since the discovery of triggering of RNA interference activity by small
interfering RNA (siRNA) in mammalian cells, researchers have been trying to
push the RNA interference technique into clinical applications.[112]

Certain

chemical modifications could help to solve some issues faced in the use of siRNA
as a therapeutic reagent, such as serum stability, biodistribution, immune
response and pharmacokinetic properties of the siRNA. [113]
We have prepared different types of selenium modifications on nucleic
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acids for X-ray crystallography purpose. However, none of the selenium
modifications have been tested for siRNA activities. In contrast, all kinds of thiol
modifications have been tested for siRNA activities to improve nuclease stability
and selectivity. Therefore, we prepared PSe-siRNA and evaluated their RNAi
effect in cells. Based on the experimental results above, the RNAi activity from
PSe-siRNA, especially from double stranded modified siRNA, was stronger than
others.

This was probably due to the longer life time for double stranded

modified siRNA. The cell death rate from double strand modified siRNA was also
the highest.

Except in the experiment result 3.3.3.2, siRNA 4 did not show

significant cell growth inhibition.

The reason for the cause of the higher cell

death rate from modified siRNA has not yet been conclusive. It is likely that the
triphosphate at 5’ end of siRNA did not play a role in affecting the cell death rate.
The remaining borane in tetrahydrofuran from the annealing solution in
experiment 3.3.2.1 could be the reason for a higher cell death rate for all four
types of homemade siRNA, while compared to commercial siRNA.

After

switching to DTT as the reducing agent in the annealing buffer, cell death rate of
home-made non-modified siRNA was similar to that of commercially available
siRNA. Experiment 3.3.3.3 (Figure 3.9) and Figure 3.12 indicated that double
strand selenium modification has a higher cell death rate. The effect of selenium
on cell death has to be further investigated.
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4.

SYNTHESIS

OF

4-SE-URIDINE

5’-TRIPHOSPHATE

AND

ITS

INCORPORATION INTO RNA
4.1 Introduction
Natural modifications on RNA molecules have been known for a long
time and over 100 special natural modifications on RNA have been found to date.
[114]

Although the functionalities of many modifications are still unclear, the

characterized modifications are usually located in important functional regions of
RNA, such as the pseudouridine and 2’-O-methylation on rRNA,[115] and
anticodon loop of tRNA.[114]

Besides studies on natural RNA modifications,

development of unnatural RNA modifications also has great significance on
improving biotechnology for RNA-based research tools and therapeutic methods
[116]

. Modified nucleotides can be used for research like probing the functional

groups of ribozyme
replication.[118]

[117]

and investigating the base-pairing fidelity of

Chemical modifications have also been applied to increase

siRNA serum stability and RNAi activity. [37]
It is not well-known that selenium also naturally occurs in bases of
tRNA, usually in the wobble base position, which may have some special
functions. Detailed studies about the natural Se-derivatized RNAs are rather
limited.[61, 119] Our group previously reported derivatization of DNA at 4-position
of

thymidine

(4-Se-T)

through

solid

phase

synthesis

and

enzymatic

incorporation.[79-80] In the crystal structure of the solid phase synthesized short
DNA duplex containing 4-Se-thymidine, selenium formed a hydrogen bond with
6-amino group of A on the complimentary strand.[80] It is very interesting that this
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selenium modification at 4 position of thymidine gave DNA a visible bright yellow
color. The synthesis method for 4-Se-uridine 5’-triphosphate (4-Se-UTP) and its
enzymatic incorporation was described in this dissertation to continue
development of selenium building blocks for RNA crystallography and make
potential RNA visualization tool for RNA detection.
Unlike deoxyribose modification, in the synthesis of unnatural ribose
modification, choosing the right ribose 5’ and 2’ protecting groups is important. [114]
A good 2’-hydroxyl group should be easy to introduce, stable under the particular
reaction condition and easily removed afterwards. For the synthesis of 4-Se-UTP,
the selenium at 4 position also needs to be protected from the aggressive
reaction conditions that are used for generating triphosphate.

The lack of a

methyl group at 5 position on uridine compared with thymidine also changes the
chemical property of 4-Se-urindine and makes new challenges for its synthesis
and incorporation. In this chapter, the synthesis method for 4-Se-UTP has been
described in detail and the incorporation of 4-Se-UTP into RNA was also reported
with supporting kinetics data.
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4.2 Materials and methods
4.2.1 Simple synthetic route for 4-Se-UTP
TIBS
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Figure 4.1. Synthetic route of 4-Se-UTP
Reagents

and

conditions:

(a)

TIBSCl,

DMAP,

CH2Cl2,

RT;

(b)(NCCH2CH2Se)2/NaBH4, EtOH, RT; (c) triethylamine, THF, 45 oC, 1h ; (d) 80%
acetic acid, RT, 30min; (e) Phosphorus oxychloride, proton sponge, TMP, 0 oC, 1
h; (f) tributylammonium pyrophosphate, DMF, 0 oC, 1 min, followed by 0.25 M
triethylamine carbonate, RT, 2 h; (g) 0.1 M K2CO3 in methanol and water (3:1),
RT.

TIBSCl:

2,4,6-(Triisopropylbenzene)sulfonyl

chloride;

DMAP:

4,4’-

dimethylamino-pyridine; THF: trihydroflouride; TMP: trimethyl phosphate.

As showed in Figure 4.1, the synthesis started from the partially
protected 2’-TBDMS-5’-trityl-uridine (compound 1). Considering the presence of
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bulky TBDMS group at the 2’ position, the synthesis route was simplified by using
a relatively more chemoselective TIBS (2,4,6-Triisopropylbenzenesulfonyl) group
to activate position 4, instead of the previous trizaole group, thus avoided the
protection and deprotection steps for the 3’-hydroxyl group. Without purifying this
activated intermediate (compound 2), the selenium functionality was introduced
directly by the substitution of TIBS group at position 4 with sodium 2cyanoethylselenide in good yield, which was generated by the reduction of di-(2cyanoethyl) diselenide with NaBH4 in ethanol.
compound 3 is as following:

The details for synthesis of

dichloromethane solution of 2,4,6-Trisopropyl-

Benzenessulfonyl chloride was drop wisely added to a dry dichloromethane
solution of the starting material compound 1 and 4,4’-dimethylamino-pyridine
(DMAP) under argon, followed by several drops of triethyl amine. The system
was stirred for one hour before this reaction was finished (monitor by TLC, 5%
methanol in dichloromethane). At the same time, the NaBH4 suspension (250 mg
NaBH4 in 5 mL of EtOH) was injected into a flask containing di(2-cyanoethyl)
diselenide [(NCCH2CH2Se)2, 0.45 mL, d= 1.8 g/mL, 3.0 mmol] and ethanol (8 mL)
on an ice bath and under argon. The yellow color of the diselenide disappeared
in approximately 15 min, giving an almost colorless solution of sodium selenide
(NCCH2CH2SeNa). Then, the solution of compound 1 (1.34 g, 2 mmol) was
slowly injected into this solution. The selenium incorporation step was finished in
45 min, which was checked on TLC by 5% MeOH in CH2Cl2 (product Rf = 0.68).
100 mL water was then added to the reaction flask. The solution was adjusted to
pH 7-8 using CH3COOH (10%), and was then extracted with ethyl acetate (3 x
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100 mL). The organic phases were combined, washed with NaCl (sat., 100 mL),
dried over MgSO4 (s) for 30 min, and evaporated to minimum volume under
reduced pressure. Then 5 mL methylene chloride was used to dissolve the crude
product. The crude product was purified by a silica gel column equilibrated with
hexanes/methylene chloride (1:1). The gradient used to elude the compound was
methylene chloride (CH2Cl2) with 0.5%, 1%, and 2% MeOH (500 mL each
gradient). After solvent evaporation and dry on high vacuum, the pure compound
3 was obtained as a slightly yellow foamy product (1.07 g, 81% yield).
The purified compound 3 was treated by triethylamine in THF, at 45 oC
for 1h to remove TBDMS group and purified by TLC plate. The DMTr group on
purified product was removed by 80% acetic acid, at RT for 30min.

The acetic

acid in solution was eliminated by coevaporation with toluene and ethanol (9:1)
mixture three times.

Compound 4 was purified by TLC plate once before

proceed to the next step.
4-Se-UTP (Figure 4.1. compound 6) was made using a modification of
Yoshikawa procedure.[120] Compound 4 (0.025 mmole, 9 mg) was dried in a flask
with proton sponge (1.5 eq., 0.0375 mmole, 8 mg) on high vacuum for 1 h. The
dried compound 4 and proton sponge were dissolved in 110 µL trimethyl
phosphate (TMP). Phosphorus oxide chloride (POCl3) (1.2 eq., 0.03 mmole, 2.75
µL) was added to reaction flask at 0 oC. The reaction mixture was stirred for 2 h.
Then tributyl ammonium pyrophosphate (2 eq., 0.05 mmole, 22.75 mg) was
dissolved in 0.25 mL DMF and injected into reaction flask at 0 oC. The reaction
was kept at 0 oC for 1 min after adding tributyl ammonium pyrophosphate. Then
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2.5 mL 0.25 M triethylammonium bicarbonate buffer (pH 8.5) was added to
reaction mixture, which was continually stirred for another 2 h.

Ethanol

precipitation was performed on hydrolyzed triphosphate. The protective group
was removed by treating the compound 5 with 3 eq. K2CO3 (0.1 M) in methanol
and water (3:1) at RT for 2 h. The reaction was followed by UV spectrum
scanning until the maximum and the main peak for the absorption of neutralized
solution was at 365 nm and original 312 nm peak for compound 5 completely
disappeared.

After the deprotection reaction finished, several drops of 3 M HCl

was added to neutralize the base in solution. The compound 6 was purified by
reversed phase HPLC, and it was analyzed and compared with natural TTP by
UV and HPLC after purification. The purified product was confirmed by high
resolution mass spectrometry.

4.2.2 Optimization of 4-Se-UTP in transcription
4-Se-UTP was enzymatically incorporated into RNA through both
synthetic template and plasmid template by Epicentre T7 RNA polymerase
(T7950K) with modified protocol. The 10X transcription buffer was Tris (400 mM),
spermine (20 mM), DTT (100 mM), MgCl2 (20 mM), pH 7.0. 10 mM 4-Se-UTP
was used to substitute normal 10 mM UTP. Typical final reaction was performed
under the condition of 1 µM ssDNA template and top promoter strand or 50 ng/µL
dsDNA plasmid or 6 ng/µL PCR dsDNA template, and 0.5 mM other NTP and 0.1
u/µL phosphatase. MnCl2 concentration was varied from 0 mM to 5 mM in final
transcription reaction for screening. The incorporation result was checked by
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P[α] CTP label.

4.2.3. Stability studies of 4-Se-UTP in transcription buffer
Pure 4-se-UTP has a maximum UV peak at 365 nm and a minor peak
at 262 nm. The stability of 4-Se-UTP in transcription buffer is concerned. The 4Se-UTp was treated

with 1X commercial New England Biolabs transcription

buffer (pH 7.8) plus 10 mM DTT, 10 mM DTT alone, 40 mM Tris ( pH 7.8) alone,
10 mM DTT then 40 mM Tris (pH 7.8), and 1X modified New England Biolabs
transcription buffer (pH 6.5) plus 10 mM DTT. UV spectrum was monitored every
10 min at RT.
The stability of 4-Se-UTP in homemade 1X transcription buffer, Tris (40
mM), spermine (2 mM), DTT (10 mM), MgCl2 (2.5 mM), MnCl2 (2 mM), pH 7.0,
was tested by mixing the 4-Se-UTP with 1X transcription buffer and monitoring
the UV spectrum every 10 min at RT.

4.2.4 Kinetic study of 4-Se-UTP enzymatic incorporation into RNA.
A transcription mixture with condition in 4.2.2 and 2 mM Mn2+ was
prepared without any UTP, which was separated into two equal proportions to
two tubes. Proportional UTP as stated in Method 4.2.2 was added to one tube
and equal amount of 4-Se-UTP was added to the other tube. T7 RNA polymerase
(Epicentre) was added to two tubes containing either UTP or 4-Se-UTP. From
the same time point, these tubes were incubated at 37 oC. At different time
points (0, 5, 15, 30, 60, 90, 120 150 min), 5 μL transcription solution was taken

103

out and 5 μL loading buffer was added to the mixture to end the transcription.
The result was checked by 12% denature PAGE.

4.3 Results
4.3.1 Synthesis and characterization of 4-Se-UTP
4-Se-UTP was successfully synthesized and the compound confirmed
by high resolution mass spectrum (Figure 4.2). The color of 4-Se-UTP was bright
yellow while native UTP was colorless (Figure 4.3).

4-Se-UTP had two UV

absorption peaks. The major peak was at 365 nm (Figure 4.4). The minor one
was at 260 nm. The 4-Se-UTP peaks of 365 nm and 260 nm appeared at the
same retention time RP-HPLC (Figure 4.5), which proved that pure 4-Se-UTP
has two absorption peaks. RP-HPLC program used for analysis was 20min
reaching 12.5 % ACN (in 20 mM TEA·Ac buffer, pH7) running at 1 mL/min.
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Figure 4.2. High resolution MS (ESI) of 4-Se-UTP. [M-H]- =546.8843 (calcd
546.8823).
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10 mM

UTP

4-Se-UTP

Figure 4.3. Color comparison of 10 mM UTP and 4-Se-UTP. 10 mM UTP was
colorless, while 10 mM 4-Se-UTP was yellow.

Figure 4.4. 4-Se-UTP UV absorption (blue, 262 nm and 367 nm); UTP UV abs
(red, 262 nm)
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Figure 4.5. 4-Se-UTP and UTP HPLC profiles.

4.3.2 4Se-UTP stability and transcription studies
The stability was inspected in several different buffer conditions. The
result suggested that 4-Se-UTP was not very stable in commercial New England
Biolabs T7 RNA polymerase buffer (Figure 4.6.A). The effects of DTT alone
(Figure 4.6.B), Tris buffer alone (Figure 4.6.C), and DTT plus Tris buffer (Figure
4.6.D) on 4-Se-UTP stability were also checked separately. From these results,
it was suspected that DTT would cause deselenization or oxidation under basic
conditions.

Therefore the transcription condition was adjusted to neutral and

slightly acidic conditions.

The 4-Se-UTP was relatively stable in pH 6.5

transcription buffer (Figure 4.6.G).

4-Se-UTP in homemade 1X transcription

buffer, Tris (40 mM), spermine (2 mM), DTT (10 mM), MgCl2 (2.5 mM), MnCl2 (2
mM), pH 7.0, was also considered to be relatively stable (Figure 4.6.H)
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A.

Figure 4.6.A. 4-Se-UTP stability in 1X transcription buffer (pH7.8) +10 mM DTT.
UV spectrum was scanned every 10 min for 1 h at RT. The original 365nm peak
disappeared and 282 nm oxidized DTT peak kept increasing.
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B.

Figure 4.6.B. 4-Se-UTP stability in 10 mM DTT (pH 7). UV spectrum was
scanned every 10 min for 1h at RT. The original 365nm peak got lower over the
time. The 279 nM DTT peak was stable.
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C.

Figure 4.6.C. 4-Se-UTP stability sample after the experiment from figure 4.5.B
was added 40 mM Tris pH7.8. UV spectrum was scanned every 10 min for 1h at
RT. The 365 nm peak switched to 355 nm and continued get lower over the time
and 281 nm oxidized DTT peak kept increasing.
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D

Figure 4.6.D. UV spectrum of 10 mM DTT and 40 mM Tris pH 7.8. UV spectrum
was scanned every 10 min for 1h at RT. DTT peak at 282 nm got increased over
the time.
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E

282 nm

Figure 4.6.E. UV spectrum of 10 mM DTT (pH 7). UV spectrum was scanned
every 10 min for 1h at RT.
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F.

351 nm

282 nm

Figure 4.6.F. 10 mM DTT after the experiment from Figure 4.5.E was added 40
mM Tris pH 7.8 UV spectra were scanned every 10 min for 1h at RT. The new
lines in Figure 4.5.F compared with 4.5.E. show the DTT spectrum with Tris
added.
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G.

Figure 4.6.G. 4-Se-UTP stability in 1X New England Biolabs transcription buffer
(pH 6.5) plus 10 mM DTT. UV spectrum was scanned every 10 min for 1h at RT.
The original 4-Se-UTP (green) 365 nm peak got slightly lower after mixed with
the buffer and stable over the scanning time.
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H.

4-Se-UTP
alone

Figure 4.6.H. 4-Se-UTP stability in 1X homemade transcription buffer (pH 7.0),
Tris (40 mM), spermine (2 mM). UV spectrum was scanned every 10 min for 1h
at RT. The original 4-Se-UTP (Blue) 365 nm peak got slightly lower immediately
after mixed with the buffer and relatively stable over the scanning time. The 365
nm peak did not change after adding of MgCl2 (2.5 mM) and MnCl2 (2 mM).

4.3.3 4-Se-UTP RNA incorporation
There were some problems using common T7 RNA polymerization
condition to insert 4-Se-UTP into RNA, like stability of 4-Se-UTP in the
transcription buffer and low yield of 4-Se-U-RNA. Based on previous UV stability
experiment results, the pH of the transcription buffer was adjusted from 7.9 to 7.0
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to improve the stability of 4-Se-UTP. Mn2+ could give T7 RNA polymerase more
flexibility on substrate choice, therefore, Mg2+ concentration was decreased to
2.5 mM and the best Mn2+ concentration was determined by screening
experiment (Figure4.7).

The Mn2+ enhanced both UTP and 4-Se-UTP RNA

transcription. The maximum yield for RNA transcribed by either UTP or 4-SeUTP was generated in 1.5-2.0 mM Mn2+ range. The kinetic curves for 4-Se-UTP
incorporation into RNA compared with UTP were done with the best Mn2+
concentration (2 mM) (Figure 4.8). The incorporation rate of UTP over 4-Se-UTP
by T7 RNA polymerase was 3/1.8 (Figure 4.8.C). UTP was about one fold better
than 4-Se-UTP as transcription substrate. The incorporation of 4-Se-UTP into
RNA still could not be confirmed by MALDI-TOF, only the oxidized full length
product was observed (Figure 4.9. A and B). It was unclear at which step the
oxidization happened. The possible reasons are discussed in 4.4 Discussion part.
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A

B

Figure 4.7 . Mn2+ concentration screening for the best transcription condition for
4-Se-UTP. Lane 1-11: UTP with Mn2+ gradient from 0 mM to 5 mM, increasing by
0.5 mM per tube. Lane 12-22: 1x 4-Se-UTP with Mn2+ gradient from 0 mM to 5
mM, increasing by 0.5 mM per tube. A: gel image. B: quantified data shown in
curves

116

A.

4seUTP vs UTP time course
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C.

Figure 4.8. Kinetic curves for incorporation of UTP and 4-Se-UTP into RNA using
2 mM Mn2+ transcription condition. A: gel image. B: quantified relative intensity
with curve. C: slope of the kinetic curve.
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A.

Figure 4.9.A. MALDI-TOF of native 44.1 RNA (G10A7C6U1) (calcd. [M] 8067,
Observed [M] 8070)
B.

Figure 4.9.B. MALDI-TOF of 4-Se-U 44.1 RNA (G10A7C6Use1) (calcd. [M] 8130,
Observed [M] 8070)
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4.4 Discussion
Colored

DNA/RNA

could

have

many

biotechnology research tools and diagnostic tools.

applications,

such

as

Incorporation of 4-Se-

thymidine or 4-Se-uridine into nucleic acid through solid phase synthesis has
proved to be successful.

The incorporation of 4-Se-UTP into RNA through

enzymatic reaction is still a problem; because the environments of organic
synthesis and enzymatic reaction buffer system are totally different.
It was suspected that the stability of 4-Se-UTP was related to the
presence of cation ions and DTT (research results from other lab member, which
are not included in this dissertation. These studies showed that selenium
modification in 4 position of the base was not very stable in the presence of some
divalent ions. Divalent ions can chelate with selenium and result in dimerization
and oxidization of the 4-Se-nucleoside.) The dimerized substrate most likely
would not be accepted by T7 RNA polymerase. However, DTT and the divalent
ions (either Mg2+ or Mn2+) have to be used in the transcription buffer to keep RNA
polymerase activity. The instability of 4-Se-UTP may answer the question why
no mass spectrum result for 4-Se-RNA has been observed. Unlike the highly
sensitive radioactive labeling, to prepare mass spectrum sample, a relatively
higher quantity of 4-Se-RNA sample needs be prepared and then purified. If the
substrate was dimerized, the yield of RNA transcription will be very low and make
it very difficult to purify.
Although it was exciting to discover the hydrogen bond in the crystal
structure of 4-Se-thymidine synthesized by solid phase synthesizer,[80] it is quite
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challenging to put 4-Se-UTP into RNA through enzymatic incorporation. Further
investigation is needed for using 4-SeUTP for X-ray Crystallography purposes.
The stability of selenium on nucleic acids is an important factor on choosing the
right selenium derivatization for nucleic acid X-ray crystallography.

Due to

stability issue, other sites of UTP, like 2 position on the base, probably are better
choices for base selenium modification of uridine for X-ray crystallography.
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5.

FACILE SYNTHESIS AND ANTI-TUMOR CELL ACTIVITY OF SECONTAINING NUCLEOSIDES

(This work has been published on Nucleosides, Nucleotides and Nucleic Acids, 2009, 28 (1): 5666, Jia Sheng Razin K.Momin, and Zhen Huang are listed as co-authors.)

5.1 Introduction
Due to the recent discovery that selenium is an essential trace element,[60,
121-122]

tremendous attention has been paid to the selenium research, including

chemical, biochemical, and biological investigations.[56, 122-124] Though selenium is
the most noticeable for its antioxidant properties,[123] the biological activities of
selenium are not just limited to its antioxidant abilities. The extensive research
results have indicated an inverse relationship between the selenium level in body
and the abnormalities of HIV and HPV infection, cardiomyopathy, rheumatoid
arthritis, and asthma,[125-129] although most of the mechanisms are unclear. In
addition, the clinic trial, conducted by Clark and coworkers using the seleniumenriched yeast, revealed approximately 50% reduction of the occurrence and reoccurrence of many types of cancers.[49,

122, 130]

Though selenium can be

accessed from a variety of food sources,[131] such as broccoli, Brazil nut, and
garlic,[132] Se-containing compounds have also been used as the supplements for
people with infectious diseases, such as tuberculosis or AIDS,[133-135] as these
diseases usually coincide with nutritional deficiencies.
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R1
R4

NH
N

O
R3

O

R2

1: R1= H, R2= MeSe-, R3= OH, R4= OH
2: R1= CH3, R2= H, R3= MeSe-, R4= OH
3: R1= CH3, R2= H, R3= OH, R4= MeSe-

Figure 5.1. Se-modified nucleosides.
Selenium level in the body is basically dependent on its absorption,[136-137]
though the amount of selenium in diet also plays a role. The form and oxidative
state of selenium in diet can also significantly affect its absorption and activity.[138139]

Various selenium compounds, in both inorganic and organic forms, have

been reported to have biological activities.[60,

140]

For instance, selenite and

selenomethionine are the most commonly used Se-containing compounds in the
experimental and clinic studies.[122] Development of Se-containing organic
compounds that can be used as micronutrient supplements is an important
approach to improve the disease prevention and treatment. Considering the
toxicity and absorption, it is better to synthesize organic seleno-compounds in the
forms of the naturally occurring products and the derivatives. Furthermore, Ip and
coworkers have demonstrated that methylselenol is an active metabolite of the
Se-containing

compounds,

such

as

methylselenocysteine

and

seleno-

methionine.[60, 141-143] Methylselenol, offering the high anticancer activity, can be
generated via in vivo reduction of the methylseleno-containing compounds.[57, 142]
Therefore, the organic compounds containing methylseleno (MeSe) functionality
are potential agents for anticancer application and chemoprevention.[142]
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It has been well-demonstrated that selenomethionine, containing MeSe
functionality, is better absorbed and retained in body than inorganic selenite.[139]
Though selenomethionine is commonly used as a food additive and Se-carrier,
its cytotoxicity is relatively high.[144] In addition to the Se-amino acids, it was
shown that several selenonucleobases and 8- seleno-cGMPs had anticancer
activities,[145-146] and that many natural tRNAs contain selenium-modified
nucleosides.[61, 147] Recently, our research group has pioneered and developed
selenium-derivatized nucleic acids (SeNA) for function and x-ray crystal structure
studies.[20,

69-70, 79-80]

Therefore, by taking advantage of our experiences in

selenium chemistry, we have designed and synthesized novel nucleosides
derivatized with MeSe functionality at various positions (Figure 5.1) in order to
evaluate the MeSe effect and to develop better Se-carriers for anticancer
application and chemoprevention. We describe here the simple synthesis of the
new 3’-MeSe-thymidine nucleoside and the other uridine and thymidine
derivatives modified with MeSe at the 2’and 5’ positions, and report their activity
against prostate tumor cell lines.

5.2 Material and method
5.2.1 Synthesis of MeSe-nucleosides
Most solvents and reagents were purchased and used without purification
unless mentioned otherwise. Pyridine was dried over KOH (s) and distilled under
argon. When necessary, solid reagents were dried under high vacuum. Reactions
with compounds sensitive to air or moisture were performed under argon.
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Solvent

mixtures

are

indicated

as

volume/volume

ratios.

Thin

layer

chromatography (TLC) was run on Merck 60 F254 plates (0.25 mm thick; Rf
values in the text are for the title products), and visualized under UV-light or by a
Ce-Mo staining solution (phosphomolybdate, 25 g; Ce(SO4)2.4H2O, 10 g; H2SO4,
60 mL, conc.; H2O, 940 mL) with heating. Preparative TLC was performed using
Merck 60 F254 pre-coated plates (2 mm thick). Flash chromatography was
performed using Fluka silica gel 60 (mesh size 0.040–0.063 mm) using a silica
gel:crude compound weight ratio of ca. 30:1. 1H and

13

C-NMR spectra were

recorded usingBruker-300 or 400 (300 or 400 MHz). All chemical shifts (δ) are in
ppm relative to tetramethylsilane and all coupling constants (J) are in Hz.
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Figure 5.2. Synthesis of 2’-MeSe-uridine (1). Reagents and conditions: (i)
diphenyl carbonate and NaHCO3 in DMF, heated at 120 oC for 2 hr; (ii) dimethyl
diselenide and NaBH4 in EtOH:MeOH (8:1), heated at 50oC for 3-4 hr.

2’-methylseleno-2’-deoxyuridine (1). Uridine (4.17 g, 17.1 mmol) and diphenyl
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carbonate (4.0 g, 18.7 mmol) were placed in a round-bottom flask, and N,Ndimethylformamide (5.0 mL) was added. The slurry was heated in an oil bath at
100◦C. Dry sodium bicarbonate (33 mg) was then added, and a watch glass was
used to cover the flask. The reaction mixture was heated at 120–130 ◦C for 1
hour while being monitored on TLC (methanol/methylene chloride, 2:8). After
completion, the reaction was cooled to room temperature. The precipitated
product was filtered and washed by cold methanol three times (each time 1.5
mL). The white powdered product (5) was dried on high vacuum overnight. (3.31
g, 86%). Compound [5, 2,2’-O-anhydro-1-(β-D-arabinofuranosyl)-uracil]: 1HNMR
(d6-DMSO) δ (ppm): 3.11–3.23 (m, 2H, H-5’), 3.97–4.11 (m, 1H,H-4’), 4.25–4.41
(m, 1H, H-3’), 4.91 (m, HO), 5.18 (d, J = 5.8 Hz, 1H, H-2’), 5.81 (m, HO), 5.96 (d,
J = 7.5 Hz, 1H, H-5), 6.22 (d, J = 5.8 Hz,1H, H-1’), 7.78 (d, J = 7.5 Hz, 1H, H-6).
1

H-NMR spectrum is consistent with the literature.[38,39] A suspension of sodium

borohydride (148 mg) in ethanol (1 mL) was added drop wisely to
dimethyldiselenide (0.33 g, 1.75 mmol) dissolved in ethanol (3 mL) under argon.
After the yellow solution turned colorless and there was no more bubble
formation in the reaction, the suspension of 2, 2’-anhydrouridine (5, 200 mg, 0.88
mmol) in ethanol (4 mL) was added slowly, followed by addition of methanol (2
mL). The reaction was heated at 50 ◦C for 3–4 hours before it was completed
(monitored by TLC, 10% MeOH in CH2Cl2). After evaporating all solvents, the
crude product was purified by silica-gel column chromatography (7% MeOH in
CH2Cl2). Pure product (258.5 mg, 91%) was obtained. Compound 1: 1H-NMR
(MeOD, 400 MHz): δ 1.99 (s, 3H, 2’-Se-CH3), 3.18–3.55 (m, 1H, 2’-H), 3.74–3.83

125

(m, 2H, 5’-H), 4.03–4.06 (m, 1H, 3’-H), 4.35–4.37 (m, 1H, 4’-H), 5.76 (d, 1H, J =
8.1 Hz, 5-H), 6.28 (d, 1H, J = 8.4 Hz, 1’-H), 7.99 (d, 1H, J = 8.1 Hz, 6-H);
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C-

NMR (100 MHz, CDCl3+DMSO-d6) δ: 8.21 (SeCH3), 53.10 (C-2’), 67.28 (C-5’),
77.46 (C-3’), 91.48 (C-4’), 94.38 (C-1’), 107.39 (C-5), 145.51 (C-6), 155.66 (C-2),
168.51 (C-4); ESI-MS: molecular formular C10H14N2O5Se, observed (M+Na+):
344.9950 (calc. 344.9966).
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Figure 5.3. Synthesis of 3’-MeSe-thymidine (2). Reagents and conditions: (i)
MsCl/TEA/THF, at room temperature for 30 min; (ii) dilute NaOH (aq) in EtOH,
reflux for 2.5 hr; (iii) dimetheyl diselenide and NaBH4 in dioxane, heated at 93 oC
for 2 hr; (iv) 80% HOAc (aq) treatment.

3’-methylseleno-3’-deoxythymidine (2). This compound was synthesized from
5’-DMT thymidine in four steps. The first step (I) was mesylation of the 3’ position
of 5’-DMT thymidine. Without purification of the mesylate intermediate, the
second step (II) allowed the intramolecular cyclization, thereby forming
compound 7. This cyclic compound was purified by flash chromatography. The
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third step (III) involved the introduction of the methylseleno group at the 3’
position. After the detritylation with trichloroacetic acid (IV), the target compound
2 was purified by chromatography. Step (I): After placing 6 (1.44 g, 2.69 mmol) in
a round-bottom flask and drying it under high vacuum for 30 minutes, dry THF
(26.4 mL) and triethylamine (1.1 mL, 7.95 mmol, 3 equiv.) were injected into the
flask under argon. Methanesulfonyl chloride (247 µL, 3.18 mmol, 1.2 equiv.) was
slowly injected into the flask in an ice bath and under dry argon. After stirring the
reaction for 10 minutes at 0 ◦C, the reaction flask was placed and stirred at room
temperature for 30 minutes. After monitoring the reaction by TLC to confirm its
completion, methanol (1 mL) was added to quench the reaction. After
evaporation of all solvents under reduced pressure, the crude product was
redissolved in ethyl acetate and the salts were filtered out. The solvent was
evaporated again under reduced pressure to afford the crude product.
Step (II): The crude product from step (I) was redissolved in ethanol (250
mL), and NaOH (13.75 mL, 0.2 M aqueous solution, 2.75 mmol, 1.04 eq.) was
added subsequently. The reaction was completed after 2.5-hour reflux (monitored
by TLC, 5% MeOH in CH2Cl2). The 90% solvent was evaporated under reduced
pressure, and water (100 mL) was subsequently added. The crude product was
then extracted with EtOAc (3 × 25 mL). The organic phases were combined and
dried over anhydrous MgSO4 for 20 minutes. After the filtration and solvent
evaporation under reduced pressure, the crude product was purified by flash
chromatography (0 to 5% methanol in CH2Cl2, gradient). The pure product was
dried on high vacuum to afford compound 7 as a fine white powder (1.25 g, 2.42
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mmol, 90% yield over two steps).
Step (III and IV): 7 (50 mg, 0.096 mmol) and NaBH4 (18 mg) were dried
separately on high vacuum. Dry dioxane (2.0 mL) was injected into each round
bottom flask. A brown liquid of dimethyl diselenide (13 µL, 13.4 mg, 0.071 mmol,
1.5 equiv.) was carefully injected into the flask containing NaBH4. Afterward, a
few drops of ethanol were injected into the same flask dropwise until bubble
appeared. The reaction was kept running at room temperature for 15 minutes
until the solution became colorless, followed by injecting the dioxane solution of
compound 7 into this reaction. The mixture was refluxed under argon for 2 hours
before its completion (monitoring by TLC). The solvent was evaporated under
reduced pressure and the residue was dissolved in CH2Cl2 (25mL), followed by
washing with brine (3 × 10 mL). The combined organic layers were dried with
anhydrous MgSO4, filtered and evaporated to dryness. Without further
purifications, the crude product was redissolved in CH2Cl2 (5 mL) and treated
with trichloroacetic acid (0.19 g, 1.14 mmol). The mixture was stirred (0.5–1 hour)
and followed by adding several drops of CH3CH2SH to quench the DMTr cation.
The reaction was monitored by TLC, and triethylamine was added to neutralize
the acid. After evaporation of CH2Cl2, the crude product was purified by silica gel
column chromatography using 10% methanol inmethylene chloride as eluent.
The pure product (27.8 mg) was obtained with 89% yield over two steps.
Compound 2: 1H-NMR (CDCl3,400 MHz): δ 1.90 (s, 5 -CH3), 2.07 (s, 3H, SeCH3),
2.46–2.56 (m, 2H, 2’-H), 3.44–3.55 (m, 1H, 3’-H), 3.86–4.10 (m, 2H, 5’-H), 3.96–
4.00 (m, 1H, 4’-H), 6.10 (m, 1H, 1’-H), 7.59 (s, 1H, 6-H);
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C-NMR (CDCl3, 100
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MHz), δ 3.52 (3’-SeCH3), 12.69 (5-CH3), 32.48 (C-3’), 40.14 (C-2’), 61.18 (C-5’),
85.66 (C-1’) 86.71 (C-4’), 110.82 (C-5), 136.65 (C-6), 150.48 (C-2), 164.04 (C-4);
ESI-MS: molecular formular C11H16N2O4Se, observed (M + Na+): 343.0167 (calc.
343.0173).
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Figure 5.4 Synthesis of 5’-MeSe-thymidine (3). Reagents and conditions: (i) ptoluenesulfonyl chloride, DMAP, anhydrous pyridine, 22 hr; (ii) dimethyl
diselenide, NaBH4.

5’-methylseleno-5’-deoxythymidine (3). Step (I): Thymidine (60.6 mg, 0.25
mmol), p-toluenesulfonyl chloride (97.3 mg) and DMAP (2 mg) were dried under
high vacuum in a 10-mL flask for 1 hour, and then dry pyridine (1.25 mL) was
added into the flask under argon. The reaction mixture was stirred under argon at
room temperature overnight. Step (II): To a round-bottom flask containing NaBH4
(111 mg) under argon, ethanol (1.0 mL) was added, followed by addition of
dimethyl diselenide (47.0 µL, 93 mg, 0.50 mmol). This reaction was stirred for 30
minutes in an ice-water bath and under dry argon, and the solution turned from
yellow to colorless. The tosylate suspension from Step I was injected to the
methyl selenol solution, followed by stirring at room temperature overnight. The
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solvents were evaporated under reduced pressure. The crude product was
purified by silica gel plate using 7% methanol in methylene chloride as the eluent.
The white foamy product (53.1 mg) was obtained with 80% yield (recovered
thymidine, 10.4 mg). Compound 3: 1H-NMR (CDCl3, 400 MHz): δ 1.96 (s,H, 5CH3), 2.09 (s, 3H, 2’-SeCH3), 2.26–2.33 (m, 2H, 2’-H), 2.79–2.96 (m,2H, 5’-H),
4.05–4.10 (m, 1H, 3’-H), 4.38–4.45 (m, 1H, 4’-H), 6.26 (t, 1H,J = 6.7 Hz, 1’-H),
7.29 (s, 1H, 6-H), 8.13–8.18 (br, 1H, NH, exchangeable in D2O); 13C-NMR (CDCl3,
100 MHz): δ 5.63 (2’-SeCH3), 12.46 (5-CH3),27.69 (C-2’), 40.04 (C-5’), 73.39 (C3’), 84.52 (C-4’), 85.21 (C-1’), 111.19 (C-5), 135.64 (C-6), 150.57 (C-2), 164.15
(C-4); ESI-MS: molecular formular C11H16N2O4Se, observed (M-H)−: 319.0194
(calc. 319.0197).

5.2.2 Anti-prostate tumor cell assays.
Approximately 100,000 cells of each tumor cell line were plated onto sixwell plates in duplicate and allowed 24 hours to adhere. Old media was aspirated
and the fresh media (2 mL, containing various concentrations (1.0, 10, 100, 1000,
10,000 nM) of compound 1, 2, or 3) was added. A control group with no additives
was also prepared. These plates were incubated at 37 oC in an environment
containing 5% CO2. After 96-hour incubation, the cells were trypsinized and
counted. For each test sample with a Se-nucleoside, the number of live cells was
normalized to that of the control group and plotted against the concentration of
the Se-nucleoside. IC50 values of cell growth inhibition were determined by least
squares curve fitting.
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5.3 Result and Discussion
5.3.1. Synthesis of MeSe-nucleosides

Table 5.1: Synthesized MeSe-nucleosides (1-3)
Compound

R1

R2

R3

R4

Yield%

1

-H

-SeCH3 -OH

-OH

78a

2

-CH3

-H

-SeCH3

-OH

81a

3

-CH3

-H

-OH

-SeCH3

80a

a

overall yield.
In this work, we have developed convenient synthetic routes for synthesis

of the new 3’-MeSe-thymidine nucleoside and the other uridine and thymidine
derivatives modified with MeSe at the 2’ and 5’ positions, and their overall
synthetic yields are high (MeSe-nucleosides, 1–3; Table 5.1).The synthetic route
for 2’-methylseleno-2’-deoxyuridine (1) is shown in Figure 5.2. After converting
uridine (4) to 2,2’-anhydrouridine (5) using diphenyl carbonate in hot DMF,[38,39]
we normally protected the 5’-OH of 5 to increase the anhydrouridine solubility for
the MeSe incorporation, followed by removal of the 5’-protection. In order to
avoid the 5’ protection and deprotection steps, we explored several conditions,
including hot alcohol solvent, to increase the solubility of 2,2’-anhydrouridine
while controlling the reaction regioselectivity at the 2’-α-position instead of the 2position. Without the formation of the 2-MeSe-uridine isomer, methylselenol
formed by reduction of dimethyl diselenide with NaBH4 was incorporated, in high
yield, into the anhydrouridine (5) at the 2’ α-position under the elevated
temperature. Thus, the target compound (1) was conveniently synthesized in two
steps (78% overall yield). Because of the successful MeSe incorporation to the 2’
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position of 2, 2’-anhydrouridine without the 5’-protection, we planned to use the
similar strategy to introduce MeSe functionality to the 3’-position of the 2, 2’anhydrothymidine (7).
We started the synthesis of 3’-methylseleno-3’-deoxythymidine (2) from
the partially protected thymidine, 5’-DMTrthymidine (6; Figure 5.3). After
activating the 3’-hydroxyl group of 6 through a quantitative mesylation reaction,
the mesylate intermediate (without purification) was converted to the 2, 3’anhydrothymidine

derivative

(7)

under

reflux

in

ethanol

solvent.

This

intramolecular cyclization was almost quantitative when a low concentration of
the mesylate intermediate (10 mM) was used in the presence of dilute NaOH
(10.4 mM). Via the intramolecular SN2 substitution, the α-3’-mesyl group was
displaced by the 2-oxide formed under the basic condition to give 2, 3’anhydrothymidine (7). Under higher concentrations of the mesylate or NaOH,
many by-products were formed probably due to the 3’, 2’- or 3’, 4’-mesylate
elimination. After purification of the generated 2, 3’-anhydrothymidine (7),
thymidine was functionized with MeSe functionality using a procedure analogous
to the synthesis of 2’-MeSe-U (1). Due to the higher stability of 2,3’anhydrothymidine, which has much less ring strain comparing with 2,2’anhydrouridine, higher reaction temperature was required to allow successful
incorporation of the methylseleno functionality. Without the formation of the 2MeSe-thymidine isomer, MeSe functionality was almost quantitatively introduced
to the 3’-α-position of 7. Without further purification of this Se-containing
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intermediate, its 5’-dimethoxytrityl group was quantitatively removed by 80%
acetic acid, offering the target compound (2) with 81% overall yield (four steps).
5’-Methylseleno-5’-deoxythymidine

(3)

was

synthesized,

in

the

pyridineethanol mixed solution, through a two-step reaction shown in Figure 5.4.
Since it is possible to differentiate the primary and secondary hydroxyl groups,
we used p-toluenesulfonyl chloride to selectively activate the 5’ position in
pyridine. The 5’ p-toluenesulfonyl group, a good leaving group, was displaced by
methylselenol via a SN2 substitution, thereby generating target compound 3
(80% yield in two steps).

5.3.2. Anti-Prostate Tumor Cell Evaluation
Table 5.2 Inhibition results of tumor cell growth by compound 1-3

Compounds 1–3, with relatively good solubility in aqueous solution, were
screened for their anticancer activity against prostate cancer cell lines (DU145,
CWR22, PC3, and LNCaP). We found that these MeSe-nucleosides have
anticancer effects and can generally inhibit cancer cell growth. Their IC50 values
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for the cell growth inhibition and the average cell death caused by these
nucleosides at 10 μM concentration are shown in Table 5.2. Their IC50 values
against these prostate cancer cells varied from 15 to 200 nM. Our experimental
results indicated that 5’-Se-thymidine (3) is generally more active than the other
2’ and 3’ Se-nucleosides against these prostate cancer cell lines. It is probably
easier to metabolize the Se-nucleoside containing the primary MeSe than the
secondary MeSe, thereby generating more methylselenol from 3. It was
observed that the inhibition of the tumor cell growth was proportional to the
concentrations of these MSe-nucleosides.
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